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INTRODUCTION 
“We must realize that cognitive hygiene is as important subject as oral hygiene for 
healthy and happy existence” –Aditya Ajmera. 
Cognition refers to an individual’s thoughts, knowledge, interpretation, 
understanding and ideas himself and his environment. [1]If the disturbances occur in these 
areas it leads to cognitive impairment. Loss of memory and cognitive function affects 
people worldwide; such loss may be the result of different progressive neurological 
disorders of the brain. It affects both men and women and is common in the elderly. [2] 
 
Cognitive deficit is one of the major problems associated with epilepsy, both the 
underlying pathology and drug therapy can lead to disturbances in cognitive function. 
Nootropics agents may to some extent correct some of the observed cognitive deficits. 
Piracetam (PIM) is well known for its anti-myoclonus activity and specific anti-amnesic 
activity in many experimental models is used for enhancing cognition Phenytoin is one 
drug used commonly as anti-convulsant which affect learning and memory.[3]It might be 
worthwhile to assess the use of nootropic agents as add‐on in antiepileptic therapy for 
possible protection against cognitive deficits. The antiepileptic treatment may last a 
lifetime in most patients. This implies that the nootropic agents may also need to be given 
for long periods of time and have to be chosen very carefully.  
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Phenytoin (PHT) is one of the low‐cost drug and widely prescribed antiepileptic 
agent (AED) known to cause cognitive impairment. Many studies have investigated the 
effect of phenytoin on learning, memory and psychomotor functions. Administration of 
phenytoin has been shown to significantly impair learning and memory. 
                Acetylcholine has been a special target for investigations for almost two 
decades because its deficit, among other factors, has been held responsible for senile 
dementia and other degenerative cognitive disorders, including Alzheimer’s disease. 
Major importance has been relied on acetylcholine, because of the declining number of 
Acetylcholine receptors with advancing age. Inhibitors of Acetylcholine-esterase 
(AChE), which terminates the action of acetylcholine, have been special targets for 
development. Celastrus paniculatus was in use from time immemorial to treat brain 
related disorders and to enhance learning and memory. 
The present study infer the following objectives which were derived from the 
paradigm explained above with a thrust on the understanding of the effect of Celastrus 
paniculatus seed oil (Jyothismati oil), a potential nervine on the central nervous system 
based on behavioral and biochemical study. 
According to the Centre for Disease Control and prevention (CDC), Cognitive 
decline is defined as trouble remembering, learning new things, concentrating or making 
decisions that affect everyday life. Cognitive impairment ranges from mild to severe. As 
the condition develops, a person may notice changes in their cognitive function, but still 
have success accomplishing everyday activities and living independently. More severe 
types of impairment can impact a person’s ability to control bodily movements, 
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understand the meaning or importance of something, as well as affect speech and writing 
abilities.[4] 
Cognition includes attention, memory, language, orientation, praxis, executive 
function, judgment and problem solving. Disorders of cognitionare rarely restricted to 
impairments in only one or more above domains. Instead, these disorders tend to defy 
Occam’s razor, challenging clinicians and nosologists with multiplicity, comorbidity and 
unclear boundaries. These concerns are most true in the elderly, the demographic group 
most at risk for cognitive disorders. Dementia in late life is particularly problematic in 
this regard. Existing, although often unrecognized, dementia is a major risk factor for 
superimposed delirium.  
 
Certain dementias, such as dementia with lewy bodies or late stages of 
Alzheimer’s disease, may have chronic clinical presentations virtually indistinguishable 
from delirium except for temporal onset and the lack of an identifiable acute source. 
Similarly, the course of nearly all subjects developing a progressive dementia is 
complicated by the onset of one or more distinct behavioral syndromes, including 
anxiety, depression, sleep problems, psychosis, and aggression. These symptoms can be 
as distressing and disabling as the primary cognitive disorder. Some of these behavioral 
syndromes, such as psychosis, may themselves result from independent underlying 
biology and may be additive with the primary neurodegenerative process.[5] 
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The boundaries between types of dementia and between dementia and normal 
aging can be similarly diffuse. The most common neuropathological presentations 
associated with dementia reveal mixtures of Alzheimer’s disease, vascular and lewy body 
pathologies. Pure syndromes are relatively less common, although often the dementia is 
ascribed to one of the coexisting pathologies.  Strategies regarding how to understand or 
reconcile multiple pathologies in the clinic are needed, although they lag behind. The 
development of such strategies would clearly be enhanced by a nosology within the 
coming version of Diagnostic and Statistical Manual of Mental Disorders (DSM) that 
does not preclude giving each specific diagnosis, although other central nervous system 
(CNS) or Axis I conditions are present. 
The boundary between dementia and normal aging has also been recently blurred. 
The majority of community dwelling elders who have been carefully and clinically 
evaluated and found to lack signs of dementia will nevertheless have neuropathology 
lesions of Alzheimer’s disease, infarction, or Lewy bodies at autopsy. Similarly, the 
advent of in vivo imaging of amyloid plaques indicates that many normal elderly and 
elderly with mild cognitive impairment may already have amyloid deposition throughout 
their cortex to an extent that is equivalent to that of many individuals with Alzheimer’s 
disease has been defined by the presence of cognitive symptoms.  Findings such as those 
above suggest that the time is coming when the situation will more resemble that for 
coronary artery disease, which is defined by the presence of plaques that may be silent or 
symptomatic. [5] 
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The demographic imperative with regard to cognitive disorders is clear. The 
population is rapidly aging and the age is the single largest factor for developing 
dementia and other cognitive and mental disorders. When mild cognitive impairment 
presents as an isolated amnestic symptom in late life, it strongly predicts subsequent 
onset of Alzheimer’s disease, although other conditions such as focal brain lesions, 
metabolic disturbances and alcohol use may lead to isolated amnestic disorders. In 
practice mild cognitive impairment due to underlying Alzheimer’s disease is more 
prevalent. 
 
CAUSES OF COGNITIVE IMPAIRMENT:  
 Disease affecting cognitive impairment:  
o Neurodegenerative disorders 
o Vascular causes,  
o Neurological Disease 
o Nutritional Disorders 
o Endocrine 
o Infectious 
o Metabolic 
o Drugs &Toxins [6] 
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PREVALENCE OF COGNITIVE IMPAIRMENT: 
Cognitive impairment and dementia are increasing globally and predicted to 
increase proportionately more in developing regions. It is estimated that 35.6 million 
people are currently living with dementia worldwide and that the number will nearly 
double every 20 years, reaching 115.4 million in 2050, with the majority living in 
developing countries.[7] It has been estimated that in India, the population of those aged 
over 60 years will have increased from its level of 7.7% in 2001 to 12.30% by 2025 and 
there will be nearly 150 million elderly individuals. Cognitive disability or dementia is a 
relatively common disorder among the elderly. Most people with cognitive disability live 
in low- or middle-income countries (60% in 2001, estimated to rise to 71% by 2040); the 
rate of increase in cognitive disability over the decades is around 300% for India, 
whereas it is estimated to be only 100% in high-income countries.[7] 
              A neurologically degenerative disorder is the underlying cause in the majority of 
cases of significant cognitive decline.[8]Dementia represents a substantial financial burden 
on society, one that is similar to the financial burden of heart disease and cancer. In the 
aging population, cognitive functions represent a fundamental target that is receiving the 
attention of health systems. In 2009, the prevalence of dementia among the population 
aged 60 years and older ranged from 6.5% in France (and 6.4% in Italy) to 3.4% in India 
with an average of 5.5% for members of the Convention on the Organization for 
Economic Co-operation and Development (OECD). 
In an analysis,  235 selected studies involved 44,854 patients with Dementia 
(mainly vascular dementia, Alzheimer disease and mild cognitive impairment) the 
7 
 
efficacy of symptomatic treatment for vascular dementia with Piracetam, Nimodipine, 
Aniracetam, Flunarizine, Vinpocetine, Hyperbaric oxygen, Oxiracetam and treatment  
with other alternative therapies including Acupuncture, Premarin, Statin, Butylphthalide, 
Donepezil, Huperzine A, and Lithium treatment were higher than those of other existing 
treatments for cognitive dysfunction[9] 
Epilepsy is defined as “occasional sudden excessive, rapid and local discharges of 
grey matter resulting in intermittent and stereotyped disturbance in consciousness, 
behavior, emotion, motor function or sensation that on clinical grounds is believed to 
result from cortical neuronal discharge.[10]It is a neuropsychological disorder affecting 
millions of people in world level. Disturbance of naturally existing balance between the 
concentrations of inhibitory and excitatory neurotransmitters in central nervous system 
are assumed to be main cause of convulsive episodes. There are number of drugs 
available for the treatment of epilepsy in modern therapy. But the major disadvantages 
faced is their side effects and chronic toxicity.[11] 
                Approximately 50 million people currently live with epilepsy worldwide. The 
estimated proportion of the general population with active epilepsy (i.e. continuing 
seizures or with the need for treatment) at a given time is between 4 and 10 per 1000 
people. The overall incidence is high in the first year, drops to a minimum in the third 
and fourth decades of life, and then increases again in later life. More than 75 percent of 
patients have their first seizure before 18 years of age and 12 to 20 percent have a 
familial incidence of seizures. Among adults the most common seizures are the complex 
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partial and generalized tonic clonic seizures. However, some studies in low- and middle-
income countries suggest that the proportion is much higher, between 7 and 14 per 1000 
people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year. 
In high-income countries, annual new cases are between 30 and 50 per 100 000 people in 
the general population. Hence these people who are on anticonvulsants were found to 
have cognition impairment as a sequelae.[12] 
Epileptic seizures can be primary or secondary to a neurologic condition or 
reactive to a situational factor, such as sleep deprivation or drug withdrawal. It is the 
recurrent tendency to seize and status epilepticus is prolonged or repetitive seizures 
without intervening recovery. In this condition abnormal electrical discharges are due to 
hyperexcitable neurons with postsynaptic depolarization include changes in ionic 
conductance, decreased Gamma-Aminobutyric Acid (GABA) inhibition of cortical 
excitability and increased glutamate – mediated cortical excitation. In animals, alumina-
induced membrane changes alter the ratio of intracellular to extracellular ionic 
concentration s and results in abnormal neuronal firing. 
Kainic acid, a glutamate agonist, induces seizure through increased synaptic action 
at its N-mehtyl –D- aspartate (NMDA) receptors.[13]Much work is underway on potential 
antiepileptic drugs that may act through inhibition of this excitatory receptor mechanism. 
Hence finding out of anti-epileptic drugs becomes the essential target that too with least 
adverse effect profile and this leads for the accountability of this study by using the 
herbal drugs to obtain enhancement of cognition and anti-seizure activity. 
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HERBAL DRUGS AND COGNITION:   
Herbalism (also herbal medicine or phytotherapy) is the study of botany and 
use of plants intended for medicinal purposes or for supplementing a diet. Plants have 
been the basis for medical treatments through much of human history and such traditional 
medicine is still widely practiced today. Modern medicine makes use of many plant-
derived compounds as the basis for evidence-based pharmaceutical drugs. 
Although phytotherapy may apply modern standards of effectiveness testing to herbs and 
medicines derived from natural sources, few high-quality clinical trials and standards for 
purity or dosage exist. 
The use of plants for treatment in ailments in India dates back to prehistoric times. 
Ayurveda, an ancient traditional system of medicine that has been practiced in India since 
200 B.C., employs a large number of medicinal plants used in prevention and treatment 
of wide number of diseases. One of these includes the plant C. paniculatus, known for the 
centuries as “Elixir of life”. It is considered in Ayurveda to stimulate ‘medha’ (intellect) 
and promotes ‘smruti’ (memory) and so Ayurveda recognizes it as ‘Jyotishmati’dose 
regimen. C. paniculatus may be employed as stimulant nerve tonic, rejuvenant, sedative, 
tranquilizer and diuretic. It is also used in the treatment of rheumatism, gout, leprosy, 
leucoderma, paralysis and asthma. Jyotishmati has been mentioned by Sushruta, Charaka 
and Vagbhatta as a remedy for mental illness. Charaka gave the decoction of the root or 
seed internally in prescriptions, as a brain tonic for headache, depression, swooning; as a 
laxative for cleaning digestive system. Sushruta prescribed seed oil internally for 
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neurological disorders, urinary infections, skin infections, intestinal parasites and 
externally for wound healing.  
Leaves were used internally as a purgative. Chakradatta recommended fried leaves of 
Jyotishmati for inducing menstruation. The juice of leaves was also given in opium 
poisoning as a de-addiction aid.[14] 
According to Ayurveda, depending upon the Medicinal Plants with neuro-
protection include: Alzheimer’s disease is an imbalance of vata, pitta and kapha. Medhya 
(intellectual promoting) herbs such as Convolvulus microphyllus (C. pluricaulis), 
Centella asiatica, Bacopa monnieri, Acorus calamus and Celastrus paniculatus are 
beneficial in cognitive disorders. Hemidesmus indicus(HI), commonly known as Indian 
sarsaparilla or Anantmool is a slender, laticiferous and twining shrub available  over 
costal districts of Orissa and some greater part of India . Bacopa monniera is a reputed 
nootropic plant mentioned in Ayurveda for various disorder of Central nervous system.[15] 
In our study we used Celastrus paniculatus oil which is well known for its 
cognitive benefits is taken for evaluation and a standard drug Piracetam, also an 
established drug in improving cognition impairment is also been evaluated. For this 
ailment a new drug molecule is inevitable, with this perspective this study was carried 
out. 
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SOME PLANTS USED AS MEMORY ENHANCERS: 
Plants Useful parts Active constituents 
Allium sativum Bulb Sallylcysteine 
Bocopa monniera Whole plant Bacosides A & B 
Celastrus paniculatus Seeds 
Celapagine & 
Celapanigine 
Nicotiana tobaccum Leaves Nicotine 
Withania somnifera Roots Withanolides 
Ricinus communis Beans Ricinine 
Salvia officinalis Leaves Monoferpenoid 
Ginkgo biloba Leaves Ginkgolides 
Huperzia serrate Moss Huperzine 
Uncariato mentosa Bulbs Total alkaloids 
Physostigma vennosam Beans Physostigmine 
Acorus calamus Rhizomes 
Asarone & methyl 
isoeugenol 
Terminalia chebula Rhizome Chebulic acid 
            [16] 
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AIM & OBJECTIVES: 
1. To evaluate the cognition enhancement property of Celastrus paniculatus in phenytoin 
induced cognition impairment. 
 
2. To determine the antiepileptic activity of Celastrus paniculatus. 
 
3. To assess the hepatorenal toxicity of Celastrus paniculatus. 
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INTRODUCTION 
“We must realize that cognitive hygiene is as important subject as oral hygiene for 
healthy and happy existence” –Aditya Ajmera. 
Cognition refers to an individual‟s thoughts, knowledge, interpretation, 
understanding and ideas himself and his environment.
 [1]
If the disturbances occur in these 
areas it leads to cognitive impairment. Loss of memory and cognitive function affects 
people worldwide; such loss may be the result of different progressive neurological 
disorders of the brain. It affects both men and women and is common in the elderly. 
[2]
 
 
Cognitive deficit is one of the major problems associated with epilepsy, both the 
underlying pathology and drug therapy can lead to disturbances in cognitive function. 
Nootropic agents may to some extent correct some of the observed cognitive deficits. 
Piracetam (PIM) is well known for its anti-myoclonus activity and specific anti-amnesic 
activity in many experimental models is used for enhancing cognition Phenytoin is one 
drug used commonly as anti-convulsant which affect learning and memory.
[3]
It might be 
worthwhile to assess the use of nootropic agents as add‐on in antiepileptic therapy for 
possible protection against cognitive deficits. The antiepileptic treatment may last a 
lifetime in most patients. This implies that the nootropic agents may also need to be given 
for long periods of time and have to be chosen very carefully.  
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Phenytoin (PHT) is one of the low‐cost drug and widely prescribed antiepileptic 
agent (AED) known to cause cognitive impairment. Many studies have investigated the 
effect of phenytoin on learning, memory and psychomotor functions. Administration of 
phenytoin has been shown to significantly impair learning and memory. 
                Acetylcholine has been a special target for investigations for almost two 
decades because its deficit, among other factors, has been held responsible for senile 
dementia and other degenerative cognitive disorders, including Alzheimer‟s disease. 
Major importance has been relied on acetylcholine, because of the declining number of 
Acetylcholine receptors with advancing age. Inhibitors of Acetylcholine-esterase 
(AChE), which terminates the action of acetylcholine, have been special targets for 
development. Celastrus paniculatus was in use from time immemorial to treat brain 
related disorders and to enhance learning and memory. 
The present study infer the following objectives which were derived from the 
paradigm explained above with a thrust on the understanding of the effect of Celastrus 
paniculatus seed oil (Jyothismati oil), a potential nervine on the central nervous system 
based on behavioral and biochemical study. 
According to the Centre for Disease Control and prevention (CDC), Cognitive 
decline is defined as trouble remembering, learning new things, concentrating or making 
decisions that affect everyday life. Cognitive impairment ranges from mild to severe. As 
the condition develops, a person may notice changes in their cognitive function, but still 
have success accomplishing everyday activities and living independently. More severe 
types of impairment can impact a person‟s ability to control bodily movements, 
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understand the meaning or importance of something, as well as affect speech and writing 
abilities.
[4]
 
Cognition includes attention, memory, language, orientation, praxis, executive 
function, judgment and problem solving. Disorders of cognitionare rarely restricted to 
impairments in only one or more above domains. Instead, these disorders tend to defy 
Occam‟s razor, challenging clinicians and nosologists with multiplicity, comorbidity and 
unclear boundaries. These concerns are most true in the elderly, the demographic group 
most at risk for cognitive disorders. Dementia in late life is particularly problematic in 
this regard. Existing, although often unrecognized, dementia is a major risk factor for 
superimposed delirium.  
 
Certain dementias, such as dementia with lewy bodies or late stages of 
Alzheimer‟s disease, may have chronic clinical presentations virtually indistinguishable 
from delirium except for temporal onset and the lack of an identifiable acute source. 
Similarly, the course of nearly all subjects developing a progressive dementia is 
complicated by the onset of one or more distinct behavioral syndromes, including 
anxiety, depression, sleep problems, psychosis, and aggression. These symptoms can be 
as distressing and disabling as the primary cognitive disorder. Some of these behavioral 
syndromes, such as psychosis, may themselves result from independent underlying 
biology and may be additive with the primary neurodegenerative process.
[5]
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The boundaries between types of dementia and between dementia and normal 
aging can be similarly diffuse. The most common neuropathological presentations 
associated with dementia reveal mixtures of Alzheimer‟s disease, vascular and lewy body 
pathologies. Pure syndromes are relatively less common, although often the dementia is 
ascribed to one of the coexisting pathologies.  Strategies regarding how to understand or 
reconcile multiple pathologies in the clinic are needed, although they lag behind. The 
development of such strategies would clearly be enhanced by a nosology within the 
coming version of Diagnostic and Statistical Manual of Mental Disorders (DSM) that 
does not preclude giving each specific diagnosis, although other central nervous system 
(CNS) or Axis I conditions are present. 
The boundary between dementia and normal aging has also been recently blurred. 
The majority of community dwelling elders who have been carefully and clinically 
evaluated and found to lack signs of dementia will nevertheless have neuropathology 
lesions of Alzheimer‟s disease, infarction, or Lewy bodies at autopsy. Similarly, the 
advent of in vivo imaging of amyloid plaques indicates that many normal elderly and 
elderly with mild cognitive impairment may already have amyloid deposition throughout 
their cortex to an extent that is equivalent to that of many individuals with Alzheimer‟s 
disease has been defined by the presence of cognitive symptoms.  Findings such as those 
above suggest that the time is coming when the situation will more resemble that for 
coronary artery disease, which is defined by the presence of plaques that may be silent or 
symptomatic.
 [5]
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The demographic imperative with regard to cognitive disorders is clear. The 
population is rapidly aging and the age is the single largest factor for developing 
dementia and other cognitive and mental disorders. When mild cognitive impairment 
presents as an isolated amnestic symptom in late life, it strongly predicts subsequent 
onset of Alzheimer‟s disease, although other conditions such as focal brain lesions, 
metabolic disturbances and alcohol use may lead to isolated amnestic disorders. In 
practice mild cognitive impairment due to underlying Alzheimer‟s disease is more 
prevalent. 
 
CAUSES OF COGNITIVE IMPAIRMENT: 
 
 Disease affecting cognitive impairment:  
o Neurodegenerative disorders 
o Vascular causes,  
o Neurological Disease 
o Nutritional Disorders 
o Endocrine 
o Infectious 
o Metabolic 
o Drugs &Toxins [6] 
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PREVALENCE OF COGNITIVE IMPAIRMENT: 
Cognitive impairment and dementia are increasing globally and predicted to 
increase proportionately more in developing regions. It is estimated that 35.6 million 
people are currently living with dementia worldwide and that the number will nearly 
double every 20 years, reaching 115.4 million in 2050, with the majority living in 
developing countries.
[7]
 It has been estimated that in India, the population of those aged 
over 60 years will have increased from its level of 7.7% in 2001 to 12.30% by 2025 and 
there will be nearly 150 million elderly individuals. Cognitive disability or dementia is a 
relatively common disorder among the elderly. Most people with cognitive disability live 
in low- or middle-income countries (60% in 2001, estimated to rise to 71% by 2040); the 
rate of increase in cognitive disability over the decades is around 300% for India, 
whereas it is estimated to be only 100% in high-income countries.
[7]
 
              A neurologically degenerative disorder is the underlying cause in the majority of 
cases of significant cognitive decline.
[8]
Dementia represents a substantial financial burden 
on society, one that is similar to the financial burden of heart disease and cancer. In the 
aging population, cognitive functions represent a fundamental target that is receiving the 
attention of health systems. In 2009, the prevalence of dementia among the population 
aged 60 years and older ranged from 6.5% in France (and 6.4% in Italy) to 3.4% in India 
with an average of 5.5% for members of the Convention on the Organization for 
Economic Co-operation and Development (OECD). 
In an analysis,  235 selected studies involved 44,854 patients with Dementia 
(mainly vascular dementia, Alzheimer disease and mild cognitive impairment) the 
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efficacy of symptomatic treatment for vascular dementia with Piracetam, Nimodipine, 
Aniracetam, Flunarizine, Vinpocetine, Hyperbaric oxygen, Oxiracetam and treatment  
with other alternative therapies including Acupuncture, Premarin, Statin, Butylphthalide, 
Donepezil, Huperzine A, and Lithium treatment were higher than those of other existing 
treatments for cognitive dysfunction
[9] 
Epilepsy is defined as “occasional sudden excessive, rapid and local discharges of 
grey matter resulting in intermittent and stereotyped disturbance in consciousness, 
behavior, emotion, motor function or sensation that on clinical grounds is believed to 
result from cortical neuronal discharge.
[10]
It is a neuropsychological disorder affecting 
millions of people in world level. Disturbance of naturally existing balance between the 
concentrations of inhibitory and excitatory neurotransmitters in central nervous system 
are assumed to be main cause of convulsive episodes. There are number of drugs 
available for the treatment of epilepsy in modern therapy. But the major disadvantages 
faced is their side effects and chronic toxicity.
[11]
 
                Approximately 50 million people currently live with epilepsy worldwide. The 
estimated proportion of the general population with active epilepsy (i.e. continuing 
seizures or with the need for treatment) at a given time is between 4 and 10 per 1000 
people. The overall incidence is high in the first year, drops to a minimum in the third 
and fourth decades of life, and then increases again in later life. More than 75 percent of 
patients have their first seizure before 18 years of age and 12 to 20 percent have a 
familial incidence of seizures. Among adults the most common seizures are the complex 
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partial and generalized tonic clonic seizures. However, some studies in low- and middle-
income countries suggest that the proportion is much higher, between 7 and 14 per 1000 
people. Globally, an estimated 2.4 million people are diagnosed with epilepsy each year. 
In high-income countries, annual new cases are between 30 and 50 per 100 000 people in 
the general population. Hence these people who are on anticonvulsants were found to 
have cognition impairment as a sequelae.
[12]
 
Epileptic seizures can be primary or secondary to a neurologic condition or 
reactive to a situational factor, such as sleep deprivation or drug withdrawal. It is the 
recurrent tendency to seize and status epilepticus is prolonged or repetitive seizures 
without intervening recovery. In this condition abnormal electrical discharges are due to 
hyperexcitable neurons with postsynaptic depolarization include changes in ionic 
conductance, decreased Gamma-Aminobutyric Acid (GABA) inhibition of cortical 
excitability and increased glutamate – mediated cortical excitation. In animals, alumina-
induced membrane changes alter the ratio of intracellular to extracellular ionic 
concentration s and results in abnormal neuronal firing. 
Kainic acid, a glutamate agonist, induces seizure through increased synaptic action 
at its N-mehtyl –D- aspartate (NMDA) receptors.[13]Much work is underway on potential 
antiepileptic drugs that may act through inhibition of this excitatory receptor mechanism. 
Hence finding out of anti-epileptic drugs becomes the essential target that too with least 
adverse effect profile and this leads for the accountability of this study by using the 
herbal drugs to obtain enhancement of cognition and anti-seizure activity. 
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HERBAL DRUGS AND COGNITION:   
Herbalism (also herbal medicine or phytotherapy) is the study of botany and 
use of plants intended for medicinal purposes or for supplementing a diet. Plants have 
been the basis for medical treatments through much of human history and such traditional 
medicine is still widely practiced today. Modern medicine makes use of many plant-
derived compounds as the basis for evidence-based pharmaceutical drugs. 
Although phytotherapy may apply modern standards of effectiveness testing to herbs and 
medicines derived from natural sources, few high-quality clinical trials and standards for 
purity or dosage exist. 
The use of plants for treatment in ailments in India dates back to prehistoric times. 
Ayurveda, an ancient traditional system of medicine that has been practiced in India since 
200 B.C., employs a large number of medicinal plants used in prevention and treatment 
of wide number of diseases. One of these includes the plant C. paniculatus, known for the 
centuries as “Elixir of life”. It is considered in Ayurveda to stimulate „medha‟ (intellect) 
and promotes „smruti‟ (memory) and so Ayurveda recognizes it as „Jyotishmati‟dose 
regimen. C. paniculatus may be employed as stimulant nerve tonic, rejuvenant, sedative, 
tranquilizer and diuretic. It is also used in the treatment of rheumatism, gout, leprosy, 
leucoderma, paralysis and asthma. Jyotishmati has been mentioned by Sushruta, Charaka 
and Vagbhatta as a remedy for mental illness. Charaka gave the decoction of the root or 
seed internally in prescriptions, as a brain tonic for headache, depression, swooning; as a 
laxative for cleaning digestive system. Sushruta prescribed seed oil internally for 
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neurological disorders, urinary infections, skin infections, intestinal parasites and 
externally for wound healing.  
Leaves were used internally as a purgative. Chakradatta recommended fried leaves of 
Jyotishmati for inducing menstruation. The juice of leaves was also given in opium 
poisoning as a de-addiction aid.
[14]
 
According to Ayurveda, depending upon the Medicinal Plants with neuro-
protection include: Alzheimer‟s disease is an imbalance of vata, pitta and kapha. Medhya 
(intellectual promoting) herbs such as Convolvulus microphyllus (C. pluricaulis), 
Centella asiatica, Bacopa monnieri, Acorus calamus and Celastrus paniculatus are 
beneficial in cognitive disorders. Hemidesmus indicus(HI), commonly known as Indian 
sarsaparilla or Anantmool is a slender, laticiferous and twining shrub available  over 
costal districts of Orissa and some greater part of India . Bacopa monniera is a reputed 
nootropic plant mentioned in Ayurveda for various disorder of Central nervous system.
[15]
 
In our study we used Celastrus paniculatus oil which is well known for its 
cognitive benefits is taken for evaluation and a standard drug Piracetam, also an 
established drug in improving cognition impairment is also been evaluated. For this 
ailment a new drug molecule is inevitable, with this perspective this study was carried 
out. 
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SOME PLANTS USED AS MEMORY ENHANCERS: 
Plants Useful parts Active constituents 
Allium sativum Bulb Sallylcysteine 
Bocopa monniera Whole plant Bacosides A & B 
Celastrus paniculatus Seeds 
Celapagine & 
Celapanigine 
Nicotiana tobaccum Leaves Nicotine 
Withania somnifera Roots Withanolides 
Ricinus communis Beans Ricinine 
Salvia officinalis Leaves Monoferpenoid 
Ginkgo biloba Leaves Ginkgolides 
Huperzia serrate Moss Huperzine 
Uncaria tomentosa Bulbs Total alkaloids 
Physostigma vennosam Beans Physostigmine 
Acorus calamus Rhizomes 
Asarone & methyl 
isoeugenol 
Terminalia chebula Rhizome Chebulic acid 
            
[16] 
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AIM & OBJECTIVES: 
1. To evaluate the cognition enhancement property of Celastrus paniculatus in phenytoin 
induced cognition impairment. 
 
2. To determine the antiepileptic activity of Celastrus paniculatus. 
 
3. To assess the hepatorenal toxicity of Celastrus paniculatus. 
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REVIEW OF LITERATURE 
Phenytoin was first prepared in 1908 by the German chemist Heinrich Biltz and found 
useful for epilepsy in 1936. It is one of the drugs in the World Health Organization's List of 
Essential Medicines, the most effective and safe medicines needed in a health system. It is not a 
Central nervous system depressant, some sedation occurs at therapeutic doses but does not 
increase with further dose, and rather toxic doses produce excitement and muscular rigidity. 
The most outstanding action is abolition of tonic phase of maximal electroshock seizures, with 
no effect on or prolongation of clonic phase. It limits the spread of seizure activity. Threshold 
for Pentylenetetrazole convulsions is not raised and tonic clonic epilepsy is suppressed.   
          Phenytoin (PHT) is oldest non-sedative anti-seizure drug, introduced in 1938 after a 
systematic evaluation of compounds such as Phenobarbital that altered electrically induced 
seizures in laboratory animals. It was known for decades as diphenyl hydantoin.
[17] 
Many 
studies have interrogated the side effects of phenytoin. The treatment includes anticonvulsants 
such as phenytoin was found to have major adverse effects on memory, learning, and 
psychomotor functions, where by phenytoin, in both acute and chronic administration, has been 
associated with impairment in memory and learning.
[18] 
Many epileptic patients suffer from 
cognitive impairment; both the underlying pathology and antiepileptic drug therapy can cause 
such deficits.  
Phenytoin is one of the low-cost and widely prescribed antiepileptic drugs (AED) known 
to cause cognitive impairment. Many studies have investigated the effect of phenytoin on 
learning, memory and psychomotor functions. For an optimum antiepileptic therapy, it is 
desirable to have complete seizure control without interfering cognitive effects. A combination 
of antiepileptic drugs with known nootropic agents appears to be a promising research area for 
desirable seizure control with minimal/no memory deficit. A better approach would be to use an 
agent that not only corrects the cognitive disturbances but also provides seizure protection. 
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Figure : 1: Structure of Phenytoin 
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Structure-Activity Relationship 
                      A 5-phenyl or other aromatic substituent appears essential for activity against 
generalized tonic-clonic seizures. Alkyl substituent in position 5, contribute to sedation, a 
property absent in phenytoin. The carbon 5 position permits asymmetry, but there appears to be 
little difference in activity between isomers. 
Pharmacological Effects 
 Central Nervous System 
                  Phenytoin exerts anti-seizure activity without causing general depression of the 
CNS. In toxic doses, it may produce excitatory signs and at lethal levels it produces decerebrate 
rigidity. The most significant effect of phenytoin is its ability to modify the pattern of maximal 
electroshock seizures. The characteristic tonic phase can be abolished completely but the 
residual clonic seizure may be exaggerated and prolonged. This seizure-modifying action is 
observed with many other anti-seizure drugs that are effective against generalized tonic-clonic 
seizures. By contrast, phenytoin does not inhibit clonic seizures evoked by pentylenetetrazol. 
Mechanism of Action 
                  Phenytoin reduces the repetitive firing of action potentials evoked by a sustained 
depolarization of mouse spinal cord neurons maintained in vitro. This effect is mediated by a 
slowing of the rate of recovery of voltage-activated Na
+
 channels from inactivation, an action 
that is both voltage-dependent (greater effect if membrane is depolarized) and use-dependent. 
These effects of phenytoin are evident at concentrations in the range of therapeutic drug levels 
in cerebrospinal fluid (CSF) in humans, which correlate with the free (or unbound) 
concentration of phenytoin in the serum. Within the therapeutic range, the effects on Na
+
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channels are selective and no changes of spontaneous activity or responses to iontophoretically 
applied GABA or glutamate is detected. Whereas if concentration is increased to 5- to 10-fold 
higher, multiple effects of phenytoin are apparent, including reduction of spontaneous activity 
and enhancement of responses to GABA; these effects may underlie some of the unwanted 
toxicity associated with high levels of phenytoin. 
Pharmacokinetic Properties 
                     Phenytoin is available in two types of oral formulations that differ in their 
pharmacokinetics: rapid-release and extended-release forms. Once-daily dosing is possible only 
with the extended-release formulations and due to differences in dissolution and other 
formulation-dependent factors, the plasma phenytoin level may change when converting from 
one formulation to another. Confusion also can arise because different formulations can include 
either phenytoin or phenytoin sodium. Therefore, comparable doses can be approximated by 
considering "phenytoin equivalents" but serum level monitoring is also necessary to assure 
therapeutic safety. 
The pharmacokinetic characteristics of phenytoin are influenced markedly by its binding to 
serum proteins, by the nonlinearity of its elimination kinetics and by its metabolism by hepatic 
CYPs. Phenytoin is extensively bound (~90%) to serum proteins, mainly to albumin. Small 
variations in the percentage of phenytoin that is plasma protein bound dramatically affect the 
absolute amount of free (active) drug leading to increased proportions of free drug, effects of 
which are evident in the neonate, in patients with hypoalbuminemia and uremic patients. Some 
agents can compete with phenytoin for binding sites on plasma proteins and increase free 
phenytoin at the time the new drug is added to the regimen. However, the effect on free 
phenytoin is only short-lived and usually does not cause clinical complications unless inhibition 
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of phenytoin metabolism also occurs. For example, Sodium valproate, other group of anti-
epileptic drug competes for protein binding sites of phenytoin and inhibits phenytoin’s 
metabolism, resulting in marked and sustained increases in free phenytoin. Measurement of free 
rather than total phenytoin permits direct assessment of this potential problem in patient 
management. 
Phenytoin is one of the few drugs for which the rate of elimination varies as a function of its 
concentration (i.e., the rate is nonlinear). The plasma t1/2 of phenytoin ranges between 6 and 24 
hours at plasma concentrations below 10μg/ml but increases with higher concentrations; as a 
result, plasma drug concentration increases disproportionately as dosage is increased, even with 
small adjustments for levels near the therapeutic range. 
The majority (95%) of phenytoin is metabolized in the hepatic endoplasmic reticulum by 
CYP2C9/10 and to a lesser extent CYP2C19. The principal metabolite, a parahydroxy-phenyl 
derivative, is inactive. Because its metabolism is saturable, other drugs that are metabolized by 
these enzymes can inhibit the metabolism of phenytoin and increase its plasma concentration. 
Conversely, the degradation rate of other drugs that are substrates for these enzymes can be 
inhibited by phenytoin; one such drug is warfarin and addition of phenytoin to a patient 
receiving warfarin can lead to bleeding disorders. An alternative mechanism of drug 
interactions arises from phenytoin's ability to induce diverse CYPs; co-administration of 
phenytoin and medications metabolized by these enzymes can lead to an increased degradation 
of such medications. Of particular note in this regard are oral contraceptives which are 
metabolized by CYP3A4; treatment with phenytoin can enhance the metabolism of oral 
contraceptives and lead to unplanned pregnancy. The potential teratogenic effects of phenytoin 
underscore the importance of attention to this interaction. Carbamazepine, oxcarbazepine, 
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phenobarbital, and primidone also can induce CYP3A4 and likewise might increase degradation 
of oral contraceptives.
[19]
 
The low water solubility of phenytoin hindered its intravenous use and led to production of 
fosphenytoin, a water-soluble prodrug. Fosphenytoin (CEREBYX, others) is converted into 
phenytoin by phosphatases in liver and red blood cells with a t1/2 of 8-15 minutes. Fosphenytoin 
is extensively bound (95-99%) to human plasma proteins, primarily albumin. This binding is 
saturable and fosphenytoin displaces phenytoin from protein-binding sites. Fosphenytoin is 
useful for adults with partial or generalized seizures when intravenous or intramuscular 
administration is indicated. 
The usual dose of phenytoin for seizures is the extended release formulation (100mg per 
capsule). Initial dose (in Patients not previously treated with this drug) 1 capsule orally 3 times 
a day, dosage then adjusted to suit individual requirements. 
Maintenance dose: For most adults the satisfactory maintenance dosage will be 1 capsule 3 to 
4 times a day, for others an increase up to 2 capsules 3 times a day may be made if necessary. 
Chewable tablet has a dosage of 50mg / tablet. 
Suspension: (125mg per 5 ml) initial dose (in patients not previously treated with this drug) 
5ml orally 3 times daily, dosage then adjusted to suit individual requirements, an increase in up 
to 25ml orally daily may be made necessary. 
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PHARMACODYNAMICS: 
 
Figure : 2 Mechanism of action of Phenytoin
[20]
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CENTRAL NERVOUS SYSTEM: 
Phenytoin binds to specific site on voltage-dependent sodium channels and is thought to 
exert its anticonvulsant effect by suppressing the sustained repetitive firing of neurons by 
inhibiting sodium flux through these voltage dependent channels. Phenytoin stabilizes 
membranes, protecting the sodium pump in the brain. It limits the development of maximal 
convulsive activity and reduces the spread of convulsive activity from a discharging focus 
without influencing the focus itself. 
CARDIO VASCULAR SYSTEM: 
                      Phenytoin also stabilises membranes, protecting the sodium pump in the heart. 
Phenytoin has anti arrhythmic properties similar to those of quinidine or procainamide.  
Although phenytoin has minimal effect on the electrical excitability of cardiac muscle, it 
decreases the force of contraction, depresses pacemaker action and improves atrioventricular 
conduction. It also prolongs the effective refractory period relative to the action potential 
duration. 
ADVERSE DRUG REACTIONS: 
           The toxic effects of phenytoin depend on the route of administration, the duration of 
exposure, and the dosage. When fosphenytoin, the water-soluble prodrug, is administered 
intravenously at an excessive rate in the emergency treatment of status epilepticus, the most 
notable toxic signs are cardiac arrhythmias with or without hypotension, and/or CNS 
depression. Although cardiac toxicity occurs more frequently in older patients and in those with 
known cardiac disease, it also can develop in young, healthy patients. These complications can 
be minimized by administering fosphenytoin at a rate of < 150 mg of phenytoin sodium 
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equivalents per minute. Acute oral over dosage results primarily in signs referable to the 
cerebellum and vestibular system; high doses have been associated with marked cerebellar 
atrophy.  
CNS TOXICITY: 
                   Toxic effects associated with chronic treatment also are primarily dose-related 
cerebello-vestibular effects but also include other CNS effects. These include nystagmus, 
ataxia, slurred speech, decreased coordination, and mental confusion. Dizziness, insomnia, 
transient nervousness, motor twitching, and headache have also been observed. There have also 
been rare reports of phenytoin induced dyskinesias, including chorea, dystonia, tremor, and 
asterixis. A predominantly sensory peripheral polyneuropathy has been observed in patients 
receiving long-term phenytoin therapy. 
OTHER TOXICITIES: 
                 Gingival hyperplasia occurs in around 20% of all patients on chronic phenytoin 
therapy and is probably the most common manifestation of phenytoin toxicity in children and 
young adolescents. It may be more frequent in those individuals who also develop coarsened 
facial features. The overgrowth of tissue appears to involve altered collagen metabolism. 
Toothless portions of the gums are not affected. The condition does not necessarily require 
withdrawal of medication and can be minimized by good oral hygiene. 
 
A variety of endocrine effects have been reported. Inhibition of release of anti-diuretic hormone 
(ADH) has been observed in patients with inappropriate ADH secretion. Raised sugar levels in 
blood and urine appear to be due to inhibition of insulin secretion. Rarely hyperglycemic 
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hyperosmolar non-ketotic coma complicates IV Phenytoin therapy.  Hypertrichosis is seen 
especially in children. Long term phenytoin therapy sometimes causes hyoertrophy of facial 
subcutaneous tissue, Hypertrichosis and coarsening of facial features (Phenytoin Facies).
[21]
 
Osteomalacia, with hypocalcemia and elevated alkaline phosphatase activity, has been 
attributed to both altered metabolism of vitamin D and the attendant inhibition of intestinal 
absorption of Ca
2+
. Phenytoin also increases the metabolism of vitamin K and reduces the 
concentration of vitamin K–dependent proteins that are important for normal Ca2+ metabolism 
in bone. This may explain why the osteomalacia is not always ameliorated by the administration 
of vitamin D. 
 
Hypersensitivity reactions include morbilliform rash in 2-5% of patients. Occasionally 
more serious skin reactions, including Stevens-Johnson syndrome, Toxic epidermal necrolysis, 
Fetal hydantoin syndrome, Systemic lupus erythematosus (SLE) and potentially fatal hepatic 
necrosis have also been documented. Hematological reactions include neutropenia and 
leukopenia, red-cell aplasia, agranulocytosis, and mild thrombocytopenia also have been 
encountered. Lymphadenopathy, resembling Hodgkin's disease and malignant lymphoma, is 
associated with reduced immunoglobulin A (IgA) production. Hypoprothrombinemia and 
hemorrhage have occurred in the newborns of mothers who received phenytoin during 
pregnancy; vitamin K is effective treatment or prophylaxis
.[19] 
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Plasma Drug Concentrations 
A good correlation usually is observed between the total concentration of phenytoin in 
plasma and its clinical effect. Thus, control of seizures generally is obtained with total 
concentrations above 10μg/mL, while toxic effects such as nystagmus develop at total 
concentrations around 20 μg/mL. Control of seizures generally is obtained with free phenytoin 
concentrations of 0.75-1.25μg/mL. 
Drug Interactions 
 Concurrent administration of any drug metabolized by CYP2C9 or CYP2C10 can 
increase the plasma concentration of phenytoin by decreasing its rate of metabolism ,  
 Carbamazepine, which may enhance the metabolism of phenytoin, causes a well-
documented decrease in phenytoin concentration. Conversely, phenytoin reduces the 
concentration of carbamazepine.  
 Interaction between phenytoin and phenobarbital is variable. 
 Phenytoin being an enzyme inducer, increases the mechanism of corticosteroids, oral 
contraceptives, doxycycline, rifampicin, theophylline, levodopa, Vitamin D and   
Vitamin K. 
 Enzyme inhibitors like disulfiram, isoniazid, cimetidine, chloramphenicol decrease the 
metabolism of phenytoin.
[22]
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Therapeutic Uses 
 Epilepsy 
           Phenytoin is effective against complex partial and tonic-clonic but not absence seizures. 
The use of phenytoin and other agents in the therapy of epilepsies is discussed further at the end 
of this chapter. Phenytoin preparations differ significantly in bioavailability and rate of 
absorption. In general, patients should consistently be treated with the same drug from a single 
manufacturer. However, if it becomes necessary to temporarily switch between products, care 
should be taken to select a therapeutically equivalent product and patients should be monitored 
for loss of seizure control or onset of new toxicities.
[23]
 
Other Uses 
 Trigeminal and related neuralgias  
 Cardiac arrhythmias- Refractory Ventricular Arrhythmia 
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PIRACETAM 
 
 
 
 
Figure: 3: Structure of Piracetam 
 
 
 
 
 
 26 
 
PIRACETAM 
                       Piracetam was developed in 1960s in Belgium as a ‘smart drug’. It is a recurring 
plagiaristic form of GABA, also known as aminobutyric acid. Since its discovery and 
usefulness detection, piracetam has been used as a nootropic agent for the enhancement of 
memory in human beings. It did not produce harmful and toxic effects. Austria, Germany and 
Switzerland, it is indicated in stroke and mild cognitive impairment. Levetiracetam, another 
commonly used nootropic agent was developed in 1999 to cure epilepsy. It has been licensed 
since 1999 in USA and 2000 in Switzerland. 
          Piracetam is the prototype of the nootropic agents, a class of drugs activating brain 
integrative mechanisms and improving learning and memory processes. Other nootropic agents 
include Rolziracetam, Aniracetam, Pramiracetam and Oxiracetam.  
        It is a nootropic with low contagiousness and insolubility levels and incurs a small 
number of side effects. Its effectiveness in the treatment of ischemia, cognitive impairment, 
stroke and dementia is acknowledged widely. It also contributes to the cognition enhancement 
of dyslexic and dyspraxic children. Its usefulness is equally apparent in Down syndrome 
patients whereby piracetam is employed to slow down the rapid aging of the brain. It also 
contributes as a modulator of brain metabolism, neuro-protection and neuro-plasticity. 
Piracetam is also known to have anti-seizure or antiepileptic effects. 
Characteristics of an ideal Nootropic Agent: 
a) It should protect the brain from physical and chemical injuries. 
b) It should enhance the memory and learning processes. 
c) It should act against those agents which may impair memory and behavior. 
d) It should not produce harmful and toxic effects. 
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Pharmacological Properties of Nootropics: 
Nootropics influence cholinergic function. These drugs enhance the synthesis of 
acetylcholine by increasing high affinity choline uptake at muscarinic and nicotinic receptors.  
As the human beings age advances, a depletion of acetylcholine receptors has been observed. 
Piracetam acts by enhancing the number of acetylcholine receptors in frontal region of the 
brain. So, ultimately it increases the level of acetylcholine in the brain by 30-40 %. 
            In case of dementia or Alzheimer’s disease the carbohydrate metabolism of our brain is 
declined. Brain cells produce their own ATP from glucose and sugar as they cannot get it from 
any other source. 
Piracetam acts by activating adenylate kinase enzyme that is responsible for the 
conversion of ADP in to ATP and AMP. So, this compensates the deficiency of ATP in the 
brain cells. This may ultimately serve a crucial role in preventing and curing dementia by 
recovering the oxygen and energy demand in the brain  
 It also elevate the cerebral blood supply, oxygen supply, glucose metabolism rate in 
human brain functioning which was impaired from a long period like in the case of 
multi-infarct dementia, senile dementia, pseudo dementia, poor brain blood flow.  
 It also possesses antithrombotic activity in vivo. It has been shown to normalize 
platelet aggregation in patients with acute stroke, transient ischemic attacks and 
diabetes mellitus
.[24]
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MECHANISM OF ACTION OF PIRACETAM: 
The Membrane Hypothesis: 
             Piracetam not only affects the membrane fluidity of the brain but also the membrane of 
blood platelets.  Piracetam acts by restoring the membrane fluidity. Membrane fluidity is crucial 
for the regulation of membrane transport, enzyme activity, chemical secretion, receptor binding 
nd stimulation. It has been reported that piracetam interacts with the cell membranes and 
prevented the appearance of alcohol related changes in a synthetic phosphatylcholine 
monolayer. 
           It was observed that amyloid peptide gets aggregated on the neuronal membranes and 
causes lipid disorganization within the cell membranes. Piracetam reduces the destabilizing 
effects of the amyloid peptide. This could happen as a result when piracetam interacts with 
phospholipid head groups of the cell membranes.  
            Piracetam also plays an important role in energy metabolism by enhancing the 
utilization of oxygen in the brain and enhancing the cell permeability and also the permeability 
of mitochondrial membranes to the intermediate products of Krebs’s cycle and acts as an 
antioxidant/neurotonic. It also enhances the number of acetylcholine receptors. The agents 
belonging to piracetam, oxiracetam and aniracetam stimulate AMPA type glutamate receptors 
which enhance the number of receptor binding sites for AMPA and calcium uptake. 
[21]
 
PIM (2-oxo-1-pyrolidone acetamide)-a nootropic has been shown to be an effective anti-
myoclonic agent. It has been shown to have a specific anti-amnesic activity. In addition, it has 
demonstrated a protective effect against pentylenetetrazole kindling-induced neuronal loss and 
learning deficit. However, it lacks anticonvulsant activity in the Maximal Electroshock Model 
(MES). Convincing neuroprotective functions have also been shown experimentally. Thus it 
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would be worthwhile to assess the use of Piracetam along with Phenytoin on seizure and 
cognitive functions. The central cholinergic system plays an important role in learning and 
memory. Phenytoin is known to reduce hippocampal ACh concentration. In view of this we 
also studied the effect of this combination on the brain cholinergic system. Since the majority of 
anti-epileptic drugs including PHT are known to impair motor performance, the study also 
evaluated this combination on motor function. 
[22]
 
This drug is a cyclic GABA derivative has no GABA like activity and has been called 
Nootropic meaning a drug selectively improve efficiency of higher telencephalic integrative 
activities. 
Nootropic drugs are widely used for treating neurological disorders like: 
(i) cognition/memory;  
(ii) epilepsy and seizure;  
(iii) neurodegenerative diseases;  
(iv) stroke /ischemia; 
(v) stress and anxiety. 
          
              Piracetam is not a vasodilator, does not affect total/ regional blood flow but may 
reduce the blood viscosity. In India and some other countries it has been promoted for cognition 
impairment and dementia in the elderly as well as for mental retardation in age group over 30 
years. It may benefit in cognitive disorders of cerebrovascular and traumatic origin. In the 
United Kingdom (UK), it is approved for adjunctive treatment of cortical myoclonus, but is not 
recommended for children.  
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DRUG INTERACTIONS: 
Piracetam is not metabolized in the liver. It is not plasma protein bound. So, there are very less 
chances of drug–drug interactions. The drug has been observed to increase the anticonvulsant 
activity of carbamazepine. But, there are no interactions of any other drugs with piracetam. 
[25] 
CONTRAINDICATIONS: 
Piracetam should not be administered in patients with renal disorder since it eliminated via 
kidneys and care should be taken in cases of renal insufficiency and it is strictly contraindicated 
in patients with end-stage renal disease. It is also contraindicated in patients with cerebral 
hemorrhage. It cannot be safely used in pregnant and lactating women as no study on human is 
done although no risk to fetus has been observed yet.  
 
DISEASE AFFECTING COGNITIVE IMPAIRMENT:  
 Neurodegenerative disorders:  
o Alzheimer’s Disease,  
o Dementia With Lewy Bodies,  
o Parkinson’s Disease,  
o Huntington’s Disease.  
 Vascular:  
o Infarction,  
o Binswanger’s‘ Disease.  
 Neurological Disease:  
o Multiple Sclerosis,  
o Normal Pressure Hydrocephalus, 
 Brain Tumour 
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 Nutritional Disorders:  
o Vitamin B12 Deficiency,  
o Thiamine Deficiency,  
o Niacin Deficiency. 
 Endocrine:  
o Hypothyroidism,  
o Hypercalcemia 
 Infectious:  
o Human Immunodeficiency Disease,  
o Prion Disease,  
o Neurosyphilis. 
 Metabolic:  
o Hepatic & Renal Insuffiency,  
o Wilson’s Disease,  
o Metachromatic Leukodystrophy. 
 Drugs & Toxins Affecting Cognitive Impairment: 
o Exposure to Alcohol,  
o Heavy Metals,  
o Anticholinergic Medications,  
o Carbon monoxide,  
o Irradiation.[6] 
 
 
 
 32 
 
CELASTRUS PANICULATUS: 
 
English Name: Intellect Tree, Black-Oil Plant, Climbing Staff Tree 
Hindi Name: Kondgaidh, ,Malkangani, Sankhu 
Sanskrit Name: Jyotishmati, Jyotishka, Katabhi, Kanguni 
 
 Kingdom: PLANTAE 
 Sub-Kingdom: VIRIDIPLANTAE 
 Infra Kingdom: STREPTOPHYTA (land plants) 
 Super Division: EMBRYOPHYTA 
 Division: TRACHEOPHYTA (TRACHEOPHYTES or Vascular Plants) 
 Sub Division: SPERMATOPHYTINA (SPERMATOPHYTES or Seed Plants) 
 Class: MAGNOLIOPSIDA 
 Super Order: Rosanae 
 Order: Celastrales 
 Family: Celastraceae – Bittersweet 
 Genus: Celastrus 
 Species: Celastrus Paniculatus or C. Paniculatus 
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Figure :  4
[26]
 
a) Stem: Reddish brown stem covered with small elongated white lenticels  
b) Leaves: Alternately arranged  
c) Ovate leaf  
d) Capsules: Orange colored with 3-6 seeds inside  
e) Dehisced capsule without seeds  
f) Seeds: Single capsule showing seeds enclosed by an orange-red aril. 
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This climbing shrub grows throughout India at elevations up to 1,800 m (5,900 ft).C. 
paniculatus is a deciduous vine with stems up to 10 cm (3.9 in) in diameter and 6 m (20 ft) long 
with rough, pale brown exfoliating bark covered densely with small, elongated lenticles. The 
leaves are simple, broad, and oval, obovate or elliptic in shape, with toothed margins. Medicinal 
plants with their intraspecific variation represent a chemical and medicinal goldmine as is 
evident from the strong traditions of natural drug use. Celastrus paniculatus wild, mentioned in 
Ayurveda as “Tree of life‟, was in use from time immemorial to treat brain related disorders 
and to enhance learning and memory. The Jyotishmati oil extracted from the seeds of C. 
paniculatus is known to have effect on Central Nervous System. It is used to treat acute and 
chronic immobilization stress. The oil obtained from the seeds possesses sedative and 
anticonvulsant properties. Seed oil has been found to be beneficial to psychiatric patients; and 
increase the intelligence quotient of mentally retarded children
. [27]
 
 
 
 
 
 
 
 
 
 
 35 
 
9.1: TAXONOMY OF CELASTRUS PANICULATUS:  
Botanical Description: 
Celastrus Paniculatus is the botanical name of Indian herb known as Jyotishmati and 
Malkangani. It belongs with bittersweet family named Celastraceae.  
 
 
 
 
Figure: 5 
 
Celastrus Paniculatus plant In Dhanalakshmi Srinivasan Medical College-  Herbal Garden. 
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Figure: 6 Celastrus paniculatus seeds, oil, leaves.
[26]
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MEDICINAL PARTS: 
Celastrus paniculatus Seeds and its oil are mainly used in ayurvedic medicines. Leaves 
are also used for De-addiction. Generally, leaf juice is beneficial for treating opium addiction. 
PHYTOCHEMISTRY: (Chemical Composition) 
Celastrus paniculatus Seeds contains around 30% oil content in which following 
alkaloids are present. 
 CELAPAGIN 
 CELAPANIGIN 
 CELAPANIN 
 CELASTRINE 
 PANICULATINE 
The classes of molecules most predominant in this plant appear to be: 
 Sequesterpene alkaloids and Polyalcohols.  
Overall, the phytochemical evaluation reveals the presence of: 
 Carbohydrates 
 Fixed oil 
 Glycosides 
 Cumarines 
 Tannins 
 Flavonoids 
 Saponins 
 Steroids 
 Triterpenoids  
 which have been claimed to be responsible for its therapeutic uses. 
 
 
 38 
 
The trace elements found in Celastrus paniculatus and known to be essential for humans 
and unquestionably associated with deficiency symptoms include: 
 Chromium 
 Copper 
 Iodine 
 Iron 
 Manganese 
 Molybdenum 
 Selenium 
 Zinc. 
CNS PROPERTIES: Celastrus paniculatus has well known Nootropic property. It is also used 
for improving intellect, memory loss & dementia and neurodegenerative diseases.   
OTHER PROPERTIES: 
 Analgesic 
 Nervine Stimulant 
 Digestive Stimulant 
 Carminative 
 Cardiac Stimulant 
 Diuretic 
 Aphrodisiac 
 Erectogenic 
 Anti-rheumatic 
 Anti-arthritic 
 Anti-inflammatory 
 Anti-nociceptive 
 Emmenagogue 
 Diaphoretic 
 Febrifuge 
 Thermogenic 
 Intellect promoting 
 Anti-proliferative.
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THERAPEUTIC INDICATIONS: 
Celastrus paniculatus (Malkangani) is helpful in following health conditions:  
Memory Loss, Cognitive & Concentration Problems, Rheumatic arthritis, Insomnia, Gouty 
Arthritis, Opium addiction, Opium Poisoning , Bradycardia, Impotence, Facial paralysis, 
Sciatica, Secondary Amenorrhea. 
Celastrus Paniculatus benefits are: Seeds are used in powder form and taken with 
milk. Its seeds have effects on brain, mind, nerves, joints and bones, Improves Intellect.  
The plants usage has been extensively researched with promising results to treat 
neurodegenerative diseases such as Alzheimer’s. Mice receiving Celastrus paniculatus 
showed significant memory enhancement. 
Apart from neurological properties, the alcoholic extracts of Celastrus paniculatus seeds 
(AlcE) possess significant antinociceptive and antiinflammatory activity in-vivo. 
Histological studies show less cholesterol deposits in the aorta of animals fed with seed 
extract of Celastrus paniculatus compared to the induced hypercholesterolemic animals not 
given Celastrus paniculatus supplement. It helps in reducing the activites of HMG-CoA 
reductase, glucose 6-phosphate dehydrogenase and malate dehydrogenase which are 
associated with cholesterol synthesis.  
1. Memory loss &Dementia: It is memory booster herb, which improves recall and 
retention span & as brain tonic for increasing memory. Seeds and oil both are 
effective in forgetfulness and memory disorders. Malkangani should be used in 
dosage of 5 to 15 drops in milk. Seeds can be taken in powdered form in dosage of 1 
gram with milk. In dementia, it stops its progress by preventing cell damage in the 
brain. It increases glutathione and catalase levels and decreases malondialdehyde 
(reactive species) in the brain, which might be responsible for its antioxidant, 
neuroprotective and cognitive-enhancing actions.  
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2. Neurodegenerative Diseases: The neuroprotective effects might be due to its 
antioxidant action, which helps reducing oxidative damage of the neurons. 
MEDHYA (Nootropic) effect of Celastrus paniculatus is well-established in 
ayurveda and it is widely used for this purpose. It induces alertness, improves 
concentration, reduces rate of cell death of neurons, improves ability of thinking and 
reasoning and helps tackling stress disorders. 
 
3. Atherosclerosis & High Cholesterol: It has anti-lipidemic effects and reduces 
atherogenic index. Its use reduces total cholesterol and anti-inflammatory property 
helps reducing inflammation of blood vessels, which helps stopping or slowing 
down the progress of atherosclerotic lesions. It significantly lowers the elevated 
cholesterol and LDL cholesterol, which helps preventing cardiac diseases and 
atherosclerosis. 
 
4. Fatty Liver: Celastrus paniculatus seeds decrease fat deposition in liver. This action 
can help treating people with fatty liver syndrome or enlarged liver. 
 
5. Osteoarthritis: Celastrus paniculatus seeds possess significant anti-nociceptive 
characteristic and anti-inflammatory property, which helps reducing joint 
inflammation and joint pain. In osteoarthritis, 1 grams seed powder is recommended 
and taken with cow’s milk. It has thermogenic action, which also induces heat 
sensation in the body, so its use is suggestible in winters.  
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6. Impotence: Seeds have potent aphrodisiac, erectogenic and stimulant action. For 
improving male performance, it should be used along with milk. 
 
7. Insomnia: It has anti-stress and calming effect, which helps inducing sound sleep. 
In ayurveda, the following Jyotishmati combination is used for insomnia. 
 
           INGREDIENTS PROPORTION    
 Jyotishmati (Malkangani) Seeds 25%,  
 Jatamansi 25% 
 Misri (Crystallized Sugar) 50% 
½ teaspoon of Malkangani mixture should be taken with milk 2 hours before bedtime. If 
problem is severe, then sarpagandha powder can also be added in this mixture. 
 
8. Opium Addiction & Opium Poisoning: It acts as potent antidote for opium and 
can help people in opium addiction. It is unique ayurvedic medicine, which helps in 
opiate withdrawal, opiate de-addiction, but you should also consider other 
supporting medicines according to the symptoms of opiate withdrawal. The 
symptoms like agitation, increased tearing, anxiety, muscle aches, sleeplessness and 
runny nose are well controlled with Celastrus Paniculatus.  
 
9. Dysmenorrhea: The roasted seeds of Malkangani (Celastrus Paniculatus) along 
with China rose flower powder are used to promote easier menstruation and reduce 
menstrual cramps. It is good ayurvedic herbal remedy for primary and secondary 
dysmenorrhea. 
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10. Beriberi: Jyotishmati Oil contains a good amount of Vitamin B1 (thiamine). 
Beriberi occurs due to nutritional deficiency of VitaminB1 (thiamine). Therefore, it 
is used in dosage of 15 drops thrice a day added in the milk.  
 
11. Knee Pain: The seeds are traditionally used for knee pain treatment. It reduces pain, 
joint crepitation, inflammation and stiffness.  It is best to use during the winter 
season it has very hot potency. Its optimum dosage (500 to 1000 mg twice daily) 
can be used during winters. It has very hot potency and one can experience excess 
heat sensation in the body. Its use in summers, then dosage should be reduced to 
250mg twice daily. With high dosage, some patients may experience vertigo after 
taking Malkangani in summers. It can be continued for 3 months. 
Dosage & Administration:  
For Seeds: The general dosage of Celastrus paniculatus (Malkangani or Jyotishmati) seeds 
is as follows. 
Children: 10 mg per Kg weight, but dosage of Malkangani seeds should not exceed from 
500 mg , Adults 500 mg to 2 grams 
Pregnancy: CONTRAINDICATED 
Maximum Possible Dosage 4 grams Per Day (in divided doses)  
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                                  Figure 7: Commercially available (Pure Malkangani oil) 
 
 
The general dosage of Celastrus Paniculatus (Malkangani or Jyotishmati) Oil is as follows. 
 Children 1 to 5 drops  
 Adults 5 to 15 drops  
 Pregnancy: CONTRAINDICATED 
Maximum Possible Dosage 45 drops Per Day (in divided doses) 
Safety Profile: Generally, low dosage (around 500 mg) of Celastrus Paniculatus seeds is 
well tolerated and likely safe in all kinds of patients. According to ayurveda, Celastrus 
paniculatus (Jyotishmati or Malkangani) has very hot potency and acrid in nature, which is 
likely to increase Pitta in the body. Therefore, it is recommended in patients with Vata and 
Kapha body type or having Vata and Kapha dominant symptoms. 
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Side Effects: Inappropriate dosage or wrong use in Pitta dominant people of Celastrus 
Paniculatus seeds or oil can lead to following:  
 Restlessness 
 Giddiness 
 Heat sensation 
 Burning sensation 
 Excessive sweating  
 
Pregnancy & Lactation: 
Celastrus paniculatus (Jyotishmati/Malkangani) can also act as abortifacient and may lead 
to miscarriage in pregnant women, Hence contraindicated, if you are trying to conceive, 
during pregnancy and postpartum period. 
Contraindications: 
 Hyperacidity 
 Bleeding disorders 
 Pregnancy 
 When  trying to conceive 
 Postpartum period 
 30 days before and after surgery 
 Uterine heavy bleeding 
 Heavy menstruation.[28] 
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WHY ANIMAL MODELS FOR THIS STUDY? :  
In recent years, the practice of using animals for biomedical research has come 
under severe criticism by animal protection and animal rights. Use of animal in research 
is a moral issue because animals are harmed in experimentation, from such things as 
confinement, fear [from handling], pain and early death. Those against, contend that the 
benefit to humans does not justify the harm to animals. Many people also believe that 
animals are inferior to humans and very different from them, hence results from animals 
cannot be applied to humans. Those in favor of animal testing argue that experiments on 
animals are necessary to advance medical and biological knowledge. 
Animal models of cognitive impairment are critically important for determining 
the neural bases of learning, memory, and attention. These cognitive functions are the 
result of complex interactions of a variety of neural systems and thus cannot be well 
studied by simple in vitro models. Animal models of cognitive impairment are critical for 
determining the neural basis of cognitive function as well as for testing the efficacy of 
potential therapeutic drugs and the neurocognitive toxicity of environmental 
contaminants and drugs of abuse. A variety of models have used classic monkey, rat, and 
mouse models. Newer, non-mammalian complementary models with fish, flies, and 
flatworms are being developed. These will play an important role in both high-throughput 
screening of potential toxic or therapeutic compounds and in the determination of the 
neuromolecular bases of cognitive function
.[29] 
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Mice are becoming increasingly valuable in efforts to determine the molecular bases of 
cognitive function. In addition, genetically manipulated mice are increasingly being used 
in the development of models for new drug development. For these uses it is important to 
devise a valid, reliable, and quick battery of tests to determine cognitive function in mice. 
Application of transgenic mice to problems presented by amyloid deposition with aging 
is an especially promising forum for the development of new treatments for Alzheimer’s 
disease and other aging related cognitive impairments. Pharmacological models have 
shown that acetylcholine plays key roles in the neural bases of cognitive functions. 
Cholinergic-receptor knockout mice are being used to good effect in determining the role 
of various aspects of the cholinergic systems in cognitive function. 
 
Animal models can quite well simulate specific syndromes of cognitive 
impairment where the inciting faction is well known. Prime examples of this approach 
include studies of aging and neurotrauma. Aging studies, especially with long-lived 
species such as monkeys, readily demonstrate aging-induced cognitive impairment and 
serve as a fine basis for developing new treatments and novel drugs. Neurotrauma causes 
cognitive impairment in animal models in quite similar ways as in humans. The specific 
mechanisms underlying such impairment and the therapeutic treatments for it can be well 
studied in animal models. 
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New non-mammalian models of cognitive impairment are being developed. These 
models are sometimes called alternative models but are better termed complementary 
models, because they are best used not in place of mammalian models but to complement 
them. Mammalian and non-mammalian models each have their own sets of advantages 
and disadvantages, which can be used in a mutually complementary fashion in a strategy 
of research advancement. Mammals have a high degree of neuroanatomic similarity to 
humans, but they are generally expensive and time consuming models to use.  
Animal models of cognitive impairment play crucial roles in the characterization of 
toxicants that cause cognitive dysfunction and the identification of potential new drugs 
for treating cognitive dysfunction, as well as providing critical insight into the neural 
bases of cognitive function and dysfunction. There are a variety of important issues 
specific to each model and in general across models that must be considered if these 
models are to be used productively.
[25]
 
 
NEED FOR ANIMAL EXPERIMENTS: 
Animal studies are mandatory because at the current level for studying the 
pathogenesis of different disease, to undertake drug trials, vaccines to alleviate suffering 
in the humans it is necessary. In vitro alternate methods cannot replace animal 
experimentation totally, but can work only as adjuncts and reduce the number of animals 
to the extent possible. To achieve an effective anti-convulsive therapy, it is expected to 
attain complete seizure control without interrupting any cognitive effects caused by 
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phenytoin and the cognitive deficits can be improved with Celastrus paniculatus herbal 
plant as this study is focused. 
There are various tests to assess the learning and memory in animal models – rats and 
mice. 
They are: 
1) Pole climbing apparatus test 
2) Spontaneous alteration behavior on a plus maze test 
3) Morris water maze test 
4) Radial arm maze test 
5) Hebb’s William maze test 
6) Barnes maze test. 
7) T – maze test 
8) Object recognition tests 
 
Among these above test pole climbing test and 8 radial arm maze tests has been taken for 
our study to assess the learning and memory in mice animal models. 
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NEURO TRANSMITTERS IN CENTRAL NERVOUS SYSTEM RESEARCH 
STUDIES:   
Neurotransmitters are chemicals that travel across the synapse and allow 
communication between neurons throughout the brain and body. They are the chemical 
messengers in humans and are associated with several CNS disorders .Plant drugs can be 
used as agonist / antagonist/ modulators to neurotransmitters to treat Alzheimer’s disease, 
Parkinson’s disease etc.  
The following are the certain neurotransmitters and its functions:  
1. Acetylcholine: It is an excitatory neurotransmitter in CNS involved in wakefulness, 
attentiveness, learning and memory, anger, aggression sexuality and thirst. 
2. Dopamine: It also an excitatory neurotransmitter in CNS involved in control and 
posture. If the dopamine is elevated or low there will be inattention, forgetfulness. 
3. Nor- epinephrine: It helps to make epinephrine, Elevated levels causes anxiety and 
mood dampening effects and low levels causes decreased focus and sleep cycle problems. 
4. Epinephrine: It is an excitatory neurotransmitter in CNS, will be elevated when 
Attention deficit hyperactivity disorder symptoms are present. Long term stress and 
insomnia causes its levels to be depleted. 
5. Serotonin: It is a monoaminergic neurotransmitter, 5HT1A is found to be involved in 
psychiatric disorders like depression, schizophrenia and anxiety and becomes the target 
of these diseases
.[30] 
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NEED FOR NEWER MOLECULES FOR COGNITION ENHANCEMENT: 
Since phenytoin is the first line choice for seizure disorder in allopathic medicine 
and on long term therapy leads to impaired cognition, so it is mandatory to have a drug 
for seizure without disturbing cognition, there is a need for therapy in other modes of 
branches of medicine, we found that there are herbal drugs which is found to enhance 
cognition. Since there are fewer studies on it, so we decided to carry our work with herbal 
drug. 
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MATERIAL AND METHODS: 
 
ANIMALS: 
 Male Swiss Albino Mice of 30–45 g weight 72 Nos. were purchased from 
King’s Institute Guindy, Chennai Tamilnadu and transported to Animal house 
of DSMCH 
 Diet - standard pellets for mice - purchased in King’s institute Guindy. 
 The animals were housed in polypropylene cages (22.5 x 35.5 x l5cm) with 
false mesh to avoid coprophagy and controlled temperature (25 ± 2°C), 
humidity (50-55%) and light (12h-light-dark cycle) environment. 
 Weight will be measured at baseline. 
 The mice were allowed to acclimatize for these conditions for one week 
and the animals were permitted for free access to a standard pellet diet and 
tap water. 
DRUGS: 
1. Dilantin suspension product of Pfizer Inc,  
2. Nootropil syrup product of UCB laboratories, 
3. Collection of Celastrus paniculatus seed oil: The oil was acquired from 
Deve Herbes New Delhi, from reputed herbal pharmaceutical company by 
placing an order through Amazon online purchasing of 50 ml bottle named 
as pure Malkangani oil. 
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CHEMICALS: 
 Acetylthiocholine iodide,  
 5,5- dithiobis ( 2- nitrobenzoic acid ) [DTNB],  
 1% Tween-20(solubilising agent)  
 Dimethyl sulphoxide (solvent),  
 Ophthaldialdehyde (OPT) reagent: (20 mg in 100 ml conc. HCl)  
Purchased from “SRL DIAGNOSTICS CHENNAI.TAMILNADU”. 
 
 0.4M HCl, Sodium acetate buffer (pH 6.9) 
 5M NaOH,   
 0.1M Iodine solution (in Ethanol):  
 Na2 SO3 sol. ((0.5 g Na SO in 2 ml H O + 18 ml 5 M NaOH),  
 10M Acetic acid 
Obtained from the Department of Biochemistry, Dhanalakshmi Srinivasan Medical 
College & Hospital. 
 
Drugs and Dosing Schedules 
 Phenytoin marketed as “Dilantin” in the form of suspension was administered 
orally in doses of 8, 12, and 22 mg/kg, 2 h prior to each observation.  
 Piracetam, the nootropic standard (“Nootropil” syrup) was given orally in a 
volume of 125,250, and 500 mg/kg body weight 1 h prior to each experiment.  
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 Celastrus paniculatus, the Experimental drug was given orally with doses 100,200, 
400mg kg body weight 1 h prior to each experiment. 
 Control groups were administered standard pellet diet and tap water (10 ml/kg).  
All observations were made on the day 22 after 2 hours of phenytoin and 1 hour of 
Piracetam, Celastrus paniculatus administration. During these studies, drugs were 
administered between 10 am and 12 pm. 
 
GROUPING OF ANIMALS:   
Animals were divided into 12 groups containing six animals in each group. Group 
I served as Normal control. Group II, III, and IV received Phenytoin in dose of 8mg/kg 
12mg/kg and 22 mg/kg (i.e): 0.32mg, 0.48mg, 0.88mg. Group V, VI, and VII received 
Piracetam in dose of 125mg/kg 250mg/kg, and 500mg/kg (i.e): 5mg, 10mg, 20 mg. 
Group VIII, IX, and X received Celastrus paniculatus oil in the dose of 100mg/kg 
200mg/kg and 400 mg/kg (i.e) 4mg, 8mg, 16mg. Group XI received Phenytoin (12 
mg/kg) and Piracetam (250 mg/kg) (i.e.) 0.48mg, 10mg while Group XII received 
Phenytoin (12 mg/kg) and Celastrus paniculatus (200 mg/kg) (i.e): 0.48mg, 8mg  
respectively. 
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After the quarantine period the animals will be grouped as follows: 
 
[The submaximal dose of the drugs was selected for groups XI &XII] 
 
After purchasing, commercially available Celastrus paniculatus seed oil was 
emulsified with 1% Tween-20 (solubilising agent) and Dimethyl sulphoxide (solvent). 
Three different doses (100 mg, 200 mg and 400 mg / kg of body weight) of the seed oil 
was given orally to the grouped animals for 21days. 
 
GROUP I
normal control
GROUP II,III,IV
Phenytoin 8,12,22mg/kg/oral
GROUP V,VI,VII
Piracetam 
125,250,500mg/kg oral
GROUP VIII,IX,X
Celastrus paniculatus
100mg,200mg,400mg/kg 
/oral
GROUP XI
Phenytoin 12mg/kg
Piracetam 250mg/kg/oral
GROUP XII
Phenytoin 12mg/kg
celastrus paniculatus 
200mg/kg/oral
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ETHICAL APPROVAL: 
The experimental protocol was approved by the Institutional Animal Ethics 
Committee of Dhanalakshmi Srinivasan Medical College& Hospital, Perambalur, 
Tamilnadu and the study was constituted as per the rules of the committee for the 
Purpose of Control and Supervision of Experiments on Animals, India and the guidelines 
of Institutional Animal Ethics Committee (IAEC). 
 
EXPERIMENTAL PROCEDURE: 
The animals obtained as mentioned above was transported through well-equipped 
transporting climate controlled vehicle with standard polypropylene animal cages and 
filter top appropriately covered to avoid drawing attention to animals without inhibiting 
airflow.  
The mouse were received in the quarantine room and acclimatized for a week with 
free access to standard pellet diet and tap water and monitored for its wellbeing and 
reduction in introduction of pathogens into an established colony.  
All animals were observed for signs of illness, injury or abnormal behavior by 
animal house-incharge person. Any abnormality was monitored to ensure timely 
veterinary medical care. 
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TOXICITY STUDIES: 
Acute and chronic toxicity studies were already done for this Celastrus paniculatus 
oil in various studies. Hence to reduce the death of small animals- mice, these studies 
were not performed and the doses were followed accordingly.[27] 
      They were placed inside polypropylene cages with false mesh to avoid 
coprophagy with free access to standard pellet and tap water. The weight of the 
individual animals was measured.  
The animals set to be trained and evaluated respectively as follows: 
 Three independent assessors were training each animal for 5 minutes for 3days 
with interval led trials for each experimental methods and was allowed for free 
access to a standard pellet diet and tap water. 
 
Acute study: 
           On the 1st day the drugs were given between 10-12 am, that is phenytoin 8mg/kg, 
12mg/kg, 22mg/kg 2hr prior to observation and piracetam 125mg/kg, 250mg/kg, 
500mg/kg, celastrus paniculatus 100mg/kg, 200mg/kg, 400mg/kg 1hr before observation 
orally which was followed by experimental methods and findings were validated  
accordingly. 
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1. RADIAL ARM MAZE APPARATUS TEST: 
 
                                   8  Radial arm maze apparatus. 
 
            The eight arm radial maze apparatus for mice consisted of an equally spaced arms 
(30 x 6 x 15 cm) radiating from an octagonal central platform. Two types of memory 
assessed are reference memory and working memory. 
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 The animals were kept in restricted diet to maintain a bodyweight of 85%.The 
animals are subjected to trials individually for 5 minutes per day for two days to explore 
the maze. Before the commencement of the behavioral assessment, all groups of mice 
were semi-starved over a period of 48 hrs in order to motivate them towards food reward 
to acclimatize the mice. 
  
Partially baited task: Here, four of the eight arms were baited and the mice were trained 
to choose only the baited arms. This task permits discerning of reference memory and 
working memory components of spatial memory. 
 
An entry into an unbaited arm was regarded as a reference memory error and any 
re-entry either to a baited or unbaited arm was considered as a working memory error. 
The maze should be cleaned with 70% ethanol and four of the arms (2, 3, 6 and 8) were 
baited with food reinforcement. The mice were placed in the centre of the octagon and 
were allowed a free choice. An arm choice was recorded when a mice eats a bait or 
reached the end of an arm. 
            
The maze arms were not rebaited, so only the first entry into the baited arm was 
recorded as a correct choice. The trial continued until the mice entered all the four baited 
arms or 5 minutes had elapsed. After the end of the trial, the mice were returned to the 
home cages and subjected to second trial after an inter-trial interval of l hour. Training 
was continued till the mice attained the criteria of 80% correct choice. 
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Data taken from 4 trials was recorded and represented as blocks and then analyzed 
for percent correct choice, reference and working memory errors. Percent correct choice 
was calculated by dividing the number of correct entries by the total number of entries 
and multiplying by 100. An entry into an unbaited arm was considered a reference 
memory error (RME) and any re-entry was considered as a working memory error 
(WME). 
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2. POLE CLIMBING APPARATUS TEST: 
 
 
                           Cook’s pole climbing apparatus. 
 
Cook’s Pole Climbing Apparatus use to study cognitive function, mainly a 
response to conditioned stimuli during learning & its retention. The apparatus has an 
experimental chamber (25 × 25 × 25 cm) with the floor grid in a soundproof enclosure.  
 
Scrambled shock (6mA) is delivered to the grid floor of the chamber composed of 
stainless steel rods. A pole of  2.5 cm in diameter, hangs inside the chamber through a 
hole in the upper center of the chamber. 
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The study mouse was placed in the chamber and allowed to explore the chamber 
for 45 seconds. Conditioned stimulus (CS) i.e. buzzer signal was turned on and 
unconditioned stimulus (US) i.e. electric shock delivered through grid floor for 45 
Seconds. 
 Animal learned to associate the buzzer with the impending foot shock and was 
capable of avoiding the foot shock by climbing the pole after buzzer signal. Avoidance 
response will be defined as climbing reaction time 10 Seconds. 
Every mouse was subjected to maximum 5 trials on 1st day, and 24 hrs later, 
mouse was  subjected to relearning trials (2nd day 3 trials and on 3rd day one trial) and 
transfer latency was noted to check the retention of Conditioned Avoidance Response 
(CAR) and Escape response (ER). Animals were screened by using this model and those 
who demonstrated at least one escape response either on day one or two were included in 
the study. The values were observed accordingly. 
 
 
 
 
 
 
62 
 
3. INCREASING CURRENT ELECTROSHOCK SEIZURES(ICES) : 
 
                                  Electro convulsometer  
The increasing current electroshock seizures (ICES) was proposed by kitano et al and 
modified by Marwah et al was used for evaluation of the anticonvulsant effect of the 
drugs which used in this study.[31] A current of 2 mA electroshock to each mice via ear 
electrodes was delivered as a single train of pulses (for 0.2 s) was given with linearly 
increasing intensity of 2 mA/2 s using an Electro-convulsometer. 
The current at which the appearance of tonic hind limb extension (HLE) occurred was 
recorded as the seizure threshold current. When no tonic hind limb extension was 
observed by a current of 30 mA, electroshock was terminated. 
Findings was noted & validated. The mouse was allowed for free access to a 
standard pellet diet and tap water and further studies continued. 
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CHRONIC STUDY:  
This study starts on the 2nd day after the acute study and drugs Phenytoin, 
Piracetam and Celastrus paniculatus was given daily in the dose which is mentioned 
above and was allowed for free access to a standard pellet diet and tap water, if any 
restriction of diet is needed will be followed. 
 The drugs were given till 22nd day, for a period of 21days and the methods (i.e) 
radial arm maze test, Pole climbing apparatus test is performed. Then observations are 
noted and validated. 
After validation the mices was sacrified by using 80% carbondioxide by using 
euthanasia [32] chamber and Blood samples obtained through cardiac puncture for liver 
function tests and renal function tests and finally decapitation was done and whole brain 
was carefully removed from the skull. Liver and Kidney samples were sent to 
Department of Pathology, DSMCH for Histopathological examination.  
The fresh whole brain was weighed and transferred to a glass homogenizer and 
homogenized in an ice bath after adding 10 volumes of 0.9% w/v sodium chloride 
solution and centrifuged & supernatant liquid was used for AChE, Nor-adrenaline, 
Dopamine ,Serotonin  activity. 
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BIO-CHEMICAL TEST:  
Validation of blood and Estimation of neurotransmitters were done by using UV-
spectrophotometer, Fluorescence spectro-flurimeter from St. Joseph college of Arts & 
Science after getting the permission of the committee members, Tiruchirapalli. The 
values were Noted and evaluated. Blood investigations were performed at Friends 
diagnostics laboratory, Sastri road, Tiruchirapalli, Tamilnadu. 
Estimation of Brain Acetyl‑cholinesterase Activity: 
The method proposed by Hestrin was used for the estimation of whole brain 
acetyl-cholinesterase (AChE) activity and was based on the development of yellow color 
resulting due to the reaction of thiocholine with dithiobisnitrobenzoate ions.  
Spectrophotometric measurements were made forth extent of rate of formation of 
thiocholine from acetylcholine iodide in the presence of tissue cholinesterase. The 
treatment of sample was first done with 5,5’‑dithionitrobenzoic acid followed by 
determination of optical density (at 412 nm) of the yellow color compound formed during 
the reaction every minute for a period of 2 min was measured. AChE activity was 
calculated using the following formula. 
R = σ O.D × Volume of assay (3 ml)/E × mg of protein, 
 Where R = Rate of enzyme activity in “n” mole of acetylthiocholine iodide 
hydrolyzed/minute/mg protein, 
σ O.D = Change in absorbance/minutes. 
E = Extinction coefficient = 13600/M/cm statistical analysis.[33] 
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ESTIMATION OF NORADRENALINE AND DOPAMINE: 
 
Reagents 
1. 0.4M HCl 
2. Sodium acetate buffer (pH 6.9) 
3. 5M NaOH 
4. 0.1 M Iodine solution (in Ethanol) 
5. Na2 SO3 sol. ((0.5 g Na SO in 2 ml H O + 18 ml 5 M NaOH) 
6. 10M Acetic acid 
 
Procedure 
To the 0.2 ml of aqueous phase, 0.05 ml 0.4 M HCl and 0.1 ml of EDTA / Sodium 
acetate buffer ( H6.9)was added, followed by 0.1 ml iodine solution(0.1 M in ethanol) for 
oxidation.  
The reaction was stopped after 2 min by addition of 0.1 ml Na2SO3 solution, 0.1 
ml Acetic acid is added after 1.5 min.  
The solution was then heated to 100°C for 6 min when the sample again reached 
room temperature, excitation and emission spectra was read from the spectrofluorimeter.        
The readings was taken at 330 -375nm for dopamine and 395 -485 nm for nor-
adrenaline.[33] 
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ESTIMATION OF SEROTONIN 
The serotonin content was estimated by the method of Schlumpf. 
 
Reagents 
1. Ophthaldialdehyde (OPT) reagent: (20 mg in 100 ml conc. HCl). 
 
Procedure 
To 0.2 ml aqueous extract 0.25 ml of OPT reagent was added. The fluorophore 
was developed by heating to 100°C for 10 min.  
After the samples reached equilibrium with the ambient temperature, readings was 
taken at 360nm -470 nm in the spectrofluorimeter.[33] 
 
 
STATISTICAL ANALYSIS 
The expression of data was done as mean ± standard deviation. The normally distributed 
data was subjected to one‑way ANOVA followed by Dunnett’s test. P< 0.05 was 
considered significant. 
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RESULTS: 
Acute studies:  
Acclimatization of the animals was done for 10 days and mice was grouped and 
training was given, followed by training for radial arm maze apparatus test was given and 
each animal was trained with 4 trials and with pole climbing apparatus each animal were 
given 9 trials and the drugs were given orally.  
On Day 1,  
 Group I (Control group) : Standard pellet diet and tap water.  
 Group II, III and IV  : Phenytoin suspension- 0.32mg, 0.48mg and  0.88mg  
  respectively 
 Group V, VI and VII : Piracetam- 5mg, 10mg and 20 mg respectively 
 Group VIII, IX, X   : Pure Malkangani oil 4mg, 8mg and 16mg  
  respectively 
 Group XI   : Phenytoin & Piracetam 0.48mg and 10mg  
  respectively 
 Group XII    : Phenytoin &(Celastrus paniculatus) Pure Malkangani  
  oil 0.48mg and 8mg respectively. 
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Chronic studies: 
 The same drugs & dosages were continued for a period of 21 days and on 22
nd
 
day behavioral and biochemical assessment was performed. 
Euthanasia were done using Carbon dioxide Anesthesia in CO2 chamber and brain 
was dissected and centrifuged and biochemical analysis of neurotransmitters was 
performed. Histopathological examination was done and laboratory tests for Liver 
function test & Renal function tests was carried out. 
 
Behavioural study: 
Group I: In both ACUTE & CHRONIC STUDY the weight is almost equal. Other 
parameters are not significant with p values (P>0.05). 
A) Radial arm maze test (RAM): Right entries for acute & chronic study are 
0.17, for wrong entry is 0.75, Re-entries is 0.41, Total entries are 0.45 and the 
time taken for that was 0.2 which is also not significant. 
B) Pole climbing apparatus test values includes: Latency time: 0.08 and the 
Duration was 0.72, the Conditioned avoidance response /Escape response was: 
3 ER and 3 CAR, 5 ER and 1 CAR. 
C) ICES values were for only acute studies: 17.3333mv.  
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Comparison of  weight in grams for Acute and Chronic studies.  
In groups I, VI, IX the weight was almost equal in acute studies where as in both acute 
and chronic studies, it is reduced in group XII. 
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Comparison of Right Entries in Radial arm maze apparatus test for Acute and chronic 
studies.  
In group II, III, IV chronic administration of  phenytoin significantly reduced the right 
entries. In group XI & XII the right entries have improved compared to phenytoin group 
(group III) 
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Comparison of Wrong Entries in Radial arm maze apparatus test for Acute and chronic 
studies.  
In group II, III, IV chronic administration of  phenytoin significantly increased the wrong 
entries. In group XI and XII there is a reduction in wrong entries compared to phenytoin 
group (group III) 
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Comparison of Re-Entry in Radial arm maze apparatus test for Acute and chronic test.  
In group II, III, IV chronic administration of  phenytoin significantly Increased the Re- 
entries. In group XI & XII the re-entries are reduced compared to phenytoin group (group 
III) 
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Results of Total Entries in Radial arm maze apparatus test for Acute and chronic studies. 
In group II, III, IV chronic administration of  phenytoin significantly increases total 
entries. In group XI &  XII there is a decrease in total entries compared to the phenytoin 
group (group III) 
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Comparison of Time taken (in seconds) in Radial arm maze apparatus test for Acute and 
Chronic studies.  
In group II, III, IV chronic administration of  phenytoin significantly increases the time 
taken to complete in radial arm maze. Time taken is decereased in group XI and XII 
compared to phenytoin group (group III). 
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Comparison of Latency time in pole climbing apparatus test for Acute and Chronic 
studies.  
In group II, III, IV chronic administration of  phenytoin significantly raised the latency 
time. Latency time is reduced in group XI and XII compared to phenytoin group (group 
III) 
 
4.83 
7.67 
3.83 3.83 3.83 
6.17 
4.67 
5.17 
4.67 
6.17 
2.75 
5.16 
6.16 
14.33 
13.33 
16 
5.33 
6.67 
5.17 
6 
5.17 
6.67 
1.5 
2.83 
0
2
4
6
8
10
12
14
16
18
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Group 9 Group 10 Group 11 Group 12
LATENCY TIME IN POLE CLIMBING APPARATUS 
TEST (IN SECONDS) 
Series 1 Series 2
 76 
 
 
 
Results of duration of reaction time in pole climbing apparatus for Acute and chronic 
studies.In group II, III, IV chronic administration of  phenytoin significantly raised the 
duration. The reaction time has significantly reduced in group XI and XII compared to 
phenytoin group (group III). 
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CONDITIONED AVOIDANCE RESPONSE (CAR) / ESCAPE RESPONSE (ER) 
IN POLE CLIMBING APPPARATUS:        
   Acute          Chronic 
Group I 3- ER/3- CAR 3ER/3CAR 
Group II 4ER/2CAR 6ER 
Group III 4ER/2CAR 5ER/1CAR 
Group IV 3ER/3CAR 5ER/1CAR 
Group V 3ER/3CAR 3ER/3CAR 
Group VI 3ER/3CAR 3ER/3CAR 
Group VII 3ER/3CAR 4ER/2CAR 
Group VIII 3ER/3CAR 4ER/2CAR 
Group IX 2ER/4CAR 3ER/3CAR 
Group X 3ER/3CAR 3ER/3CAR 
Group X1 6ER 4ER/2CAR 
Group XII 3ER/3CAR 3ER/2CAR 
 
 
In group I, IX, X is almost equal (i.e) In group IX, X signifies result similar to the control 
group- 3ER/3 CAR. And in group XII  is almost similar 3 ER/2CAR. 
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Effect on Increasing current electroshock seizures on Acute studies.  
In group II, III, IV acute administration of  phenytoin significantly increased the seizure 
threshold compared to other groups. 
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Results of Bilirubin levels:   
In group II, III, IV chronic administration of  phenytoin significantly raised the levels. 
Reduction in Bilirubin levels is better with group XII than group XI. 
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Comparison of Liver Enzymes levels, chronic administration of phenytoin causes raised 
levels. 
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No obvious changes in liver enzymes in all the groups. 
 
 
 
 
Comparison of Plasma Proteins levels. 
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In groups II, III & IV chronic administration of  phenytoin significantly reduced the 
plasma protein levels. The changes in plasma protein levels are comparable in all the 
groups. 
 
 Comparison of Renal Function tests levels: In all groups urea and creatinine are almost 
equal.  
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No significant changes in Urea and Creatinine are observed in all the groups. 
 
In Group II both ACUTE & CHRONIC STUDY the weight is almost equal 
which is not significant.( P>0.05) and in Radial arm maze test (RAM): Right entries for 
acute & chronic study is significant (P=0.04), for wrong entries in acute and chronic 
study is significant (P=0.01), Re-entries for acute and chronic study is also (P=0.03) 
significant.   
 
 Total entries for acute and chronic study is not significant (P=0.07)and the Time 
taken for both the study is significant( P=0.03) and in Pole climbing apparatus test: 
Latency time in acute and chronic study is significant (P=0.0007) and the Duration 
among both the study is also significant (P=0.003, in Conditioned avoidance response 
/Escape response were : 4 Escape response and 2  Conditioned avoidance response and in 
chronic study 6 Escape response were noted which denotes the cognition impairment, 
ICES values were in acute studies: (P=0.013) were also significant. 
          
Group III, Acute and chronic the weight is almost equal which is not significant  
( P>0.05) and right entry is significant (P=0.01), wrong entry (P= 0.01),  re-entry(P= 
0.003) among total entries were (P=0.005)and the time taken were found to be (P= 
0.04)and in pole climbing apparatus Latency time were (P=0.0003)and the duration were 
(P= 0.01),  CAR/ER were 4ER/2CAR and in chronic study it is 6ER , In acute study 
ICES were P=0.001).  
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Group IV Acute and chronic the weight is almost equal which is not significant. 
( P>0.05) and right entry is (P=0.01) , wrong entries were (P= 0.002) , re-entry is  
(P= 0.03), total entry were (P= 0.028) and the time taken were (P= 0.007) , in pole 
climbing test latency time were (P= 0.004) , duration (P= .0001) and the  CAR/ER were 
4ER/2CAR and in chronic study 6ER , In ICES (P=0.0005). 
 
Group V,VI,VII  there was no significant difference in P values and in VIII, IX, X 
similar to previous groups and no significance is noted in P values, But in groups XI and 
XII there is no significance of P value noted but as such in acute and chronic comparison 
there is significance noted in the study. 
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Comparison of Neurotransmitter estimation between groups in Nor-Adrenaline after 
chronic studies.  
In group II, III, IV chronic administration of phenytoin significantly reduced the 
neurotransmitter (Nor-adrenaline) levels. The changes in group XI and XII are 
comparable. 
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Comparison of Acetyl-cholineesterase, Dopamine, Serotonin after chronic studies.  
In group II, III, IV chronic administration of phenytoin significantly decreased the 
dopamine and serotonin levels where as Acetyl-cholineesterase levels are slightly raised. 
In groups XI and XII the changes are comparable. 
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Liver function test was comparable in all the groups except Groups II, III and IV 
where we observed a little increase in bilirubin levels. But these differences were not 
significant (p>0.05). Liver enzymes, Plasma proteins and Renal function tests were 
comparable in all groups and the changes were found to be not significant (p>0.05). 
  
 
Histopathological Examination  using Eosin and Haematoxylin staining was done at 
Department of Pathology, Dhanalakshmi Srinivasan Medical College, Siruvachur, 
Perambalur and the findings were noted. 
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HISTOPATHOLOGICAL EXAMINATION OF LIVER: 
 
normal liver group 1 8mg phenytoin with 
lymphocytes- group 2 
12mg phenytoin- group 3 
 
22mg phenytoin-group 4 
100mg piracetam-group 5 
 
kupfer cells- group 6 
 
 
400mg piracetam-group 7 
normal liver- group 8 
 
kupffer cells in plant extract-
group 9 
 
 
normal portal tract with mild 
cytoplasmic vacuoles plant extract-
group 10. 
inflammatory infiltrate of the 
portal tract- Group 11 
cytoplasmic vacuolization –
group-12. 
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HISTOPATHOLOGICAL EXAMINATION OF KIDNEY:  
group 1 – normal kidney 
 
group 2 – normal kidney. 
 
group 3, 12mg phenytoin  showing 
glomerular enlargement with 
destruction of tubules. 
group 4- 22mg glomerular 
enlargement with collapse of 
tubules. 
group 5- piracetam 100mg 
kidney perivascular 
lymphocytic infiltration. 
 
group 6- glomerular enlargement 
piracetam 400mg. 
 
group 7- glomerular 
enlargement piracetam 400mg. 
 
group 8 – normal kidney. 
 
group 9- glomerular enlargement 
seen in plant extract. 
 
group 10 -glomerular 
enlargement plant extract. group 11- glomerular 
enlargement prominent. group 12- glomerular enlargement 
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DISCUSSION:  
Poor memory, lower retention and slow recall are common problems in today’s 
stressful and competitive life. The herbal drugs have shown the promising effect in the 
treatment of memory loss. The herbal products acting on the brain are called as Nootropic 
herbs (“Nootropic” is derived from Greek and means acting on the mind) and their 
isolated constituents referred to as smart drugs. Memory enhancer herbs enhance the 
memory and increase blood circulation in the brain. The herbs act either by improving 
memory or preventing neuro-degeneration by their antioxidant and anti-inflammatory 
activities. 
 
The present study was aimed to determine the usefulness of co‑administration of 
Piracetam and Celastrus paniculatus with clinically used Anti-epileptic drugs in epileptic 
patients. Our study results revealed that Piracetam or Celastrus paniculatus when co-
administered with Phenytoin impressively reverted the cognitive impairment produced by 
phenytoin. Celastrus paniculatus supported the results as obtained for established 
combination with piracetam. At the lower dose of 125 mg/kg, the enhancement in the 
percentage alternation was seen but did not show any significance, statistically. However, 
this dose was effective in reversal of Phenytoin‑induced cognitive impairment.  
The results showed that phenytoin with the dose of (12–22 mg/kg, oral) had an adverse 
effect on the cognitive function in chronic studies. Weak memory and impaired learning 
ability are the most common symptoms of cognitive impairment.     
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          Pharmacotherapy with psychoactive drugs is available for these ailments however 
they are not effective in all cases and exerts numerous side effects especially upon long 
term administration. Series of paradigms for evaluation of memory performance is 
carried out on different mechanisms. Various mazes are used conventionally to assess the 
learning and memory in animal models.  Eight Radial arm maze apparatus test 
performance is an appetite motivated task and is also useful to assess the spatial reference 
as well as spatial working memory performance and about the agents that affect these 
processes. Pole climbing apparatus is used to study cognitive function, mainly a response 
to conditioned stimuli during learning & its retention. 
 
In our study, Phenytoin (12 mg/kg, p.o.) prominently increased the “brain AChE 
activity” while on the other hand Piracetam (200mg/kg) and Celastrus paniculatus (250 
mg/kg, p.o.) lowered the “brain AChE activity” (availability of ach is more) i.e. affirming 
the countervailing action of these drugs on the cholinergic system. The impairment 
caused due to Phenytoin on learning and memory is due to interference in the cholinergic 
system also it lowers the brain Ach levels. It is worth noting that Phenytoin at 8 mg/kg, 
p.o., did not showed any impairment and increased AChE levels. This results is contrary 
to the results obtained from the study by Dubey s et al.
[30] 
Piracetam belongs to 
pyrrolidones group most of which are known to influence cholinergic functions.  
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In this study, AChE activity was reduced by Piracetam as well as by Celastrus 
paniculatus in brain. It is important to know an interesting fact in this context that co-
administration of Phenytoin with Piracetam and Celastrus paniculatus apparently 
increased the Phenytoin‑induced sharp rise in total brain AChE level showing the 
countervailing action of the cholinergic system.  
Thus, it can be said that Piracetam and Celastrus paniculatus when they were 
given as adjuvant therapy with Phenytoin, it reverted the adverse effect produced on the 
cholinergic system. It is necessary to explore the complete potential of Celastrus 
paniculatus in improving the Phenytoin‑induced cognitive impairment and getting the 
right stand in the current anti-epileptic drug therapy.  
In our study phenytoin on oral administration not only decreased Ach levels 
causing cognition impairment and also reduces nor-epinephrine levels, but the other 
neurotransmitters like dopamine and serotonin is also found to be affected. Piracetam on 
co-administration neutralize the NT levels caused by phenytoin and the test drug 
(Celastrus paniculatus) also causes increase in Dopamine, Nor-adrenaline and serotonin 
levels contrary to the study done by Bhanumathy et al in which the contents of NE, DA 
and 5-HT and their metabolites in the brain were significantly decreased in drug treated 
group. 
[31]
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In view of certain CNS disorders such as depression, psychosis, we sacrificed the 
animals and evaluated the NTs levels to estimate the exact magnitude of the problem.  
In other studies Celastrus paniculatus oil on oral administration lead to lower 
concentration of Nor adrenaline, Dopamine and Serotonin which is discordant to our 
results.
[34]
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LIMITATION OF THE STUDY: 
 
1. In our study we have examined whole brain for the neurotransmitters estimation. 
Concentrations of them in individual parts of the brain, not been determined which 
would be more informative. 
 
2. Study was performed with commercially available oil preparation. Value of the 
study would have been higher if done using seed extract preparation. 
 
 
3. In this study, the drugs have been given orally.  If it would have been given intra-
peritoneally it would have been more enlightening. 
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SUMMARY AND CONCLUSION:  
In this study we have evaluated the cognition impairment induced by phenytoin 
with increasing dose that is 8mg/kg, 12mg/kg, 22mg/kg in animal models. But with this 
dose the cognition impairment with 8mg/kg was not produced with single dose of 
Phenytoin in acute study but with chronic administration of phenytoin the same dose 
produced cognition impairment. 
Moreover, the standard drug piracetam did not produce significant effect in normal 
animals. But with cognition impairment, significantly improved cognition. Even with 
Celastrus paniculatus oil it signifies the same effect (i.e) when there is cognition 
impairment it reverted the impairment produced by phenytoin.  
Celastrus paniculatus has long been used in ayurvedic medicine for its potent 
medicinal properties. In our study C. paniculatus oil was observed to have remarkable 
effects in raising the levels of nor epinephrine (NE), dopamine (DA) and serotonin (5-
HT) in the brain. Significant improvement was also observed in the retention ability of 
the drug treated mice. So it has been established that improvement in cognition is noted  
when there is impairment.  
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There is no significant difference in improving the cognition impairment between 
Celastrus paniculatus group and piracetam group. Further studies are needed to evaluate 
its efficacy, safety and more on this aspect in the form of clinical trials and animal studies 
to determine cognition improvement in patients taking anti-epileptic therapy especially 
phenytoin for seizure disorder and will ensure full anti-epileptic effect without causing 
cognition abnormalities.  
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ALGORITHM 
 
  
 
 
 
 
GROUP I
normal control
GROUP II,III,IV
Phenytoin
8,12,22mg/kg
GROUP V,VI,VII
Piracetam 
125,250,500mg
GROUP VIII,IX,X
Celastrus paniculatus
100mg,200mg,400mg
GROUP XI
Phenytoin 12mg/kg
Piracetam 250mg/kg
GROUP XII
Phenytoin 12mg/kg
celastrus paniculatus 200mg/kg
Animals are grouped as follows 
Drugs are administered accordingly 
Drugs administered between 10 am 
and 12 am 
(phenytoin prior 2 hours ) 
(piracetam and celastrus 
paniculatus prior 1 hour) 
Prior 
observation 
Pole climbing 
apparatus  
Radial arm maze 
apparatus 
ICES 
Acute study 
(within 24 
hrs) 
 
 Pole climbing 
apparatus  
Radial arm maze 
apparatus 
Chronic study 
(on 22th day) 
 
 
Animals are sacrificed by 80% 
carbondioxideanaesthesia using euthanasia 
chamber. 
 
 
Whole  brain specimen is homogenized with 
tissue homogenizer. 
Estimation of 
Acetylcholinesterase 
Estimation of 
dopamine and 
noradrenaline 
Estimation of 
serotonin 
Results 
obtained 
 
Results obtained 
 
On 21th day 2 hrs post 
administration of last 
dose 
 
 
Blood samples 
obtained through 
cardiac puncture for 
LFT & RFT 
s 
Animals are trained accordingly 
 Three independent assessor will be 
training each animal for 5 miniutes 
for 3days with intervelled trials. 
 The drugs are administered post 3rd 
day and  the observations are made 
for acute study 
 Followed by chronic studyon 22nd 
day.. 
 housed in polypropylene cages with false 
mesh to avoid coprophagy 
• standard pellet diet 
• TAP WATER  
• controlled temperature (25 ± 2°C) 
• humidity (50-55%) and light (12h-light-
dark cycle) 
• Baseline weight measured 
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 LABORATORY INVESTIGATIONS 
 
  
  
  
  
  
  
  
  
  
  
  
 
 
  
C) FLUORESENCE SPECTROFLUORIMETRY
GROUP 1: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and Noradrenaline 
  
GROUP 2: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and   Noradrenaline 
  
GROUP 3: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 4: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and Noradrenaline 
  
GROUP 5: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and Noradrenaline 
  
GROUP 6: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 7: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 8: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 9: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 10: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
GROUP 11: Graph showing the Optical Densities of neurotransmitter values of 
  
 
 
 
 
 
 
GROUP 12: Graph showing the Optical Densities of neurotransmitter values of 
Dopamine, Serotonin and  Noradrenaline 
  
D) UV VISIBLE SPECTROPHOTOMETRY 
 
 
 
 
 
 
  
GROUP 1: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 2: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 3: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 4: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 5: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 6: Graph showing 1 minute and 2 minutes absorbance units for 
  
 
GROUP 7: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 8: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 9: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 10: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
GROUP 11: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
  
 
 
 
 
 
 
 
GROUP 12: Graph showing 1 minute and 2 minutes absorbance units for 
Acetylcholinesterase levels 
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